Antibody or antigen binding fragment thereof, antibody drug conjugate and medical application thereof

By developing anti-CD228 antibodies with high affinity and high endocytic activity, the problems of single ADC target and low patient response rate have been solved, providing antibody-drug conjugates with high tumor suppressor activity and stability for the treatment of tumors with high CD228 expression.

CN118909114APending Publication Date: 2024-11-08SHANGHAI HANSOH BIOMEDICAL CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410561010.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-08
Filing Date
2024-05-08
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing antibody-drug conjugates (ADCs) lack sufficient target diversity to meet clinical needs. Some patients are not sensitive to MMAE toxins, necessitating the development of anti-CD228 antibodies with high affinity and high endocytic activity to improve treatment efficacy.

Method used

An anti-CD228 antibody or its antigen-binding fragment is provided, comprising specific heavy and light chain variable regions, capable of being coupled with a toxin to form an ADC, such as the toxin 9106, an inhibitor of topoisomerase I, for the treatment of various CD228-overexpressing tumors.

Benefits of technology

This has resulted in antibody-drug conjugates with high endocytic activity, strong tumor-suppressive activity, good stability, and good drug-like properties, thus enhancing their therapeutic potential for various tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004827740800000111
    Figure BDA0004827740800000111
  • Figure BDA0004827740800000121
    Figure BDA0004827740800000121
  • Figure BDA0004827740800000131
    Figure BDA0004827740800000131
Patent Text Reader

Abstract

The invention relates to an antibody or an antigen binding fragment thereof, an antibody-drug conjugate thereof and application thereof. Specifically, the present invention provides a CD228 antibody, an antigen binding fragment thereof, a CD228 antibody-drug conjugate, a nucleic acid molecule encoding the antibody and the antigen binding fragment thereof, a vector and a host cell comprising the nucleic acid molecule, and a method for preparing an antibody-coupled toxin. Also provided are pharmaceutical compositions comprising the antibodies, antigen binding fragments or antibody-coupled toxins thereof, and related pharmaceutical uses.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to an anti-CD228 antibody or an antigen-binding fragment thereof, a drug conjugate thereof, and a preparation method thereof, as well as a medical use thereof. The anti-CD228 antibody and the antibody-drug conjugate thereof can be used to prepare a drug for treating a disease or condition. Background Art

[0002] CD228, also known as Melanotransferrin / MAP97 / MFI2 / MELTF, is a glycoprotein found on the surface of melanoma cells. Its C-terminus can react with glycosylphosphatidylinositol (GPI) and then anchor to the cell membrane. The CD228 gene is located in the transferrin superfamily region of chromosome 3 and has similarity with the sequence of transferrin superfamily members, but its binding properties to iron ions have not yet been fully confirmed.

[0003] CD228 has a total length of 738 amino acids and contains two transferrin-like domains: transferrin-like domain 1 at the N-terminus and transferrin-like domain 2 at the C-terminus. Due to selective splicing, CD228 protein can form two splice bodies: full-length sequence splice body 1 and splice body 2 lacking the proximal transferrin-like domain 2. Since splice body 2 lacks transferrin-like domain 2, it cannot react with glycosylphosphatidylinositol to anchor to the cell membrane and is free outside the cell. Therefore, if antibodies or antibody-drug conjugates are used to achieve anti-tumor effects by binding to CD228 molecules on the cell membrane, preferentially targeting the proximal transferrin-like domain 2 will effectively reduce drug sedimentation and reduce drug usage.

[0004] CD228 is mainly expressed in melanoma, breast cancer, pancreatic cancer, non-small cell lung cancer, colorectal cancer, mesothelioma and other malignant tumors. Under physiological conditions, it is also expressed in some specific embryonic tissues. Because its sequence has a certain similarity with transferrin, it is believed to be related to the uptake of iron ions. Not only that, CD228 also has the characteristics of endocytosis and circulation to the cell membrane. These characteristics can be used to develop antibody-drug conjugates (ADC). Seagen, AbbVie (Stemcentrx), biOasis Technologies and other companies have developed CD228 ADC drugs.

[0005] ADC consists of three parts: antibody, linker and toxin. The payload is delivered to specific tumor sites through antibodies, reducing the exposure of the payload to non-tumor tissues, effectively improving the benefit-risk ratio of anti-tumor therapy, and increasing the therapeutic window. In recent years, the research and development of ADC drugs has made unprecedented progress. Globally, 15 ADC drugs have been launched for the treatment of different tumors. However, the drug targets currently on the market are relatively concentrated. There are three ADCs targeting HER2, namely Trastuzumab Emtansine (T-DM1), Trastuzumab Deruxtecan (DS-8201) and Vedicituzumab; there are two ADCs targeting CD22, namely Inotuzumab ozogamicin and Moxetumomab pasudotox. The limitation of insufficient target diversity makes ADC unable to meet existing clinical needs. Therefore, the development of ADCs with different targets is expected to bring better efficacy and meet different clinical needs. CD228 is such a target with great potential.

[0006] Currently, the CD228 ADC with the fastest progress is SGN-CD228A developed by Seagen, which is undergoing Phase 1 clinical trials for skin melanoma, pleural mesothelioma, HER2-negative breast cancer, non-small cell lung cancer, colorectal cancer and pancreatic ductal adenocarcinoma. SGN-CD228A is coupled to MMAE (DAR value is 8) through a new glucuronide linker and shows good anti-tumor activity in vitro. However, previous studies have shown that there are patients who are insensitive to MMAE toxins in clinical practice. Therefore, the use of different linkers and toxins is expected to improve the patient's response to the drug and increase the response rate of the patient population.

[0007] The present disclosure provides an anti-human CD228 antibody with high affinity activity and high endocytic activity, which can be coupled with a toxin to form an ADC, such as 9106, an inhibitor of topoisomerase I, for the treatment of a variety of tumors with high CD228 expression. Previous studies have shown that 9106, as a toxin that can be coupled with an antibody, has good drugability, in vivo anti-tumor activity and safety (WO2020063676A). The anti-CD228 antibody-drug conjugate disclosed in the present disclosure has the characteristics of high endocytic activity, high tumor suppression activity, good stability, and good drugability, thus having high potential for clinical treatment of tumors. Summary of the invention

[0008] The present disclosure relates to an anti-CD228 antibody or antigen-binding fragment, a conjugate (ADC) thereof with a drug, and medical uses for treating tumors.

[0009] Anti-CD228 antibodies or antigen-binding fragments

[0010] One of the objects of the present disclosure is to provide an anti-CD228 antibody or antigen-binding fragment, which comprises heavy chain and light chain variable regions, wherein the heavy chain and light chain variable regions comprise: HCDR1 as shown in SEQ ID NO:33, HCDR2 as shown in SEQ ID NO:34, HCDR3 as shown in SEQ ID NO:35, and LCDR1 as shown in SEQ ID NO:63, LCDR2 as shown in SEQ ID NO:64, and LCDR3 as shown in SEQ ID NO:65; or, HCDR1 as shown in SEQ ID NO:36, HCDR2 as shown in SEQ ID NO:37, HCDR3 as shown in SEQ ID NO:38, and LCDR1 as shown in SEQ ID NO:66, LCDR2 as shown in SEQ ID NO:67, and LCDR3 as shown in SEQ ID NO:68; or, HCDR1 as shown in SEQ ID NO:36, HCDR2 as shown in SEQ ID NO:39, HCDR3 as shown in SEQ ID NO:40, and LCDR1 as shown in SEQ ID NO:69, LCDR2 as shown in SEQ ID NO:70, and LCDR3 as shown in SEQ ID NO:71. NO:71; or, HCDR1 as set forth in SEQ ID NO:41, HCDR2 as set forth in SEQ ID NO:42, HCDR3 as set forth in SEQ ID NO:43, and LCDR1 as set forth in SEQ ID NO:72, LCDR2 as set forth in SEQ ID NO:73, and LCDR3 as set forth in SEQ ID NO:74; or, HCDR1 as set forth in SEQ ID NO:44, HCDR2 as set forth in SEQ ID NO:45, HCDR3 as set forth in SEQ ID NO:46, and LCDR1 as set forth in SEQ ID NO:75, LCDR2 as set forth in SEQ ID NO:76, and LCDR3 as set forth in SEQ ID NO:77; or, HCDR1 as set forth in SEQ ID NO:44, HCDR2 as set forth in SEQ ID NO:45, HCDR3 as set forth in SEQ ID NO:47, and LCDR1 as set forth in SEQ ID NO:78, LCDR2 as set forth in SEQ ID NO:76, and LCDR3 as set forth in SEQ ID NO:77; or, HCDR1 as set forth in SEQ ID NO:44, HCDR2 as set forth in SEQ ID NO:48, HCDR3 as set forth in SEQ ID NO:49, and LCDR1 as set forth in SEQ ID NO:40 HCDR3 shown in SEQ ID NO:47, and LCDR1 shown in SEQ ID NO:78, LCDR2 shown in SEQ ID NO:76, and LCDR3 shown in SEQ ID NO:77;or, HCDR1 as set forth in SEQ ID NO:44, HCDR2 as set forth in SEQ ID NO:49, HCDR3 as set forth in SEQ ID NO:47, and LCDR1 as set forth in SEQ ID NO:75, LCDR2 as set forth in SEQ ID NO:76, and LCDR3 as set forth in SEQ ID NO:77; or, HCDR1 as set forth in SEQ ID NO:50, HCDR2 as set forth in SEQ ID NO:51, HCDR3 as set forth in SEQ ID NO:52, and LCDR1 as set forth in SEQ ID NO:79, LCDR2 as set forth in SEQ ID NO:80, and LCDR3 as set forth in SEQ ID NO:81; or, HCDR1 as set forth in SEQ ID NO:53, HCDR2 as set forth in SEQ ID NO:49, HCDR3 as set forth in SEQ ID NO:47, and LCDR1 as set forth in SEQ ID NO:75, LCDR2 as set forth in SEQ ID NO:76, and LCDR3 as set forth in SEQ ID NO:77; or, HCDR1 as set forth in SEQ ID NO:54, HCDR2 as set forth in SEQ ID NO:55, HCDR3 as set forth in SEQ ID NO:52 : The HCDR1 shown in SEQ ID NO:56, and the LCDR1 shown in SEQ ID NO:82, the LCDR2 shown in SEQ ID NO:83, and the LCDR3 shown in SEQ ID NO:84; or, the HCDR1 shown in SEQ ID NO:57, the HCDR2 shown in SEQ ID NO:58, the HCDR3 shown in SEQ ID NO:59, and the LCDR1 shown in SEQ ID NO:85, the LCDR2 shown in SEQ ID NO:86, and the LCDR3 shown in SEQ ID NO:87; or, the HCDR1 shown in SEQ ID NO:60, the HCDR2 shown in SEQ ID NO:61, the HCDR3 shown in SEQ ID NO:47, and the LCDR1 shown in SEQ ID NO:78, the LCDR2 shown in SEQ ID NO:76, and the LCDR3 shown in SEQ ID NO:77; or, the HCDR1 shown in SEQ ID NO:60, the HCDR2 shown in SEQ ID NO:45, the HCDR3 shown in SEQ ID NO:42, and the LCDR1 shown in SEQ ID NO:88, the LCDR2 shown in SEQ ID NO:64, and the LCDR3 shown in SEQ ID NO: LCDR3 shown in NO:89. ;

[0011] One of the objects of the present disclosure is to provide an anti-CD228 antibody or antigen-binding fragment, which comprises a heavy chain and a light chain variable region, wherein the heavy chain variable region is as shown in SEQ ID NO:90, and the light chain variable region is as shown in SEQ ID NO:97; or, the heavy chain variable region is as shown in SEQ ID NO:91, and the light chain variable region is as shown in SEQ ID NO:97; or, the heavy chain variable region is as shown in SEQ ID NO:92, and the light chain variable region is as shown in SEQ ID NO:98; or, the heavy chain variable region is as shown in SEQ ID NO:93, and the light chain variable region is as shown in SEQ ID NO:98; or, the heavy chain variable region is as shown in SEQ ID NO:94, and the light chain variable region is as shown in SEQ ID NO:99; or, the heavy chain variable region is as shown in SEQ ID NO:95, and the light chain variable region is as shown in SEQ ID NO:99; or, the heavy chain variable region is as shown in SEQ ID NO:96, and the light chain variable region is as shown in SEQ ID NO:100; or, the heavy chain variable region is as shown in SEQ ID NO:96, and the light chain variable region is as shown in SEQ ID NO:101. NO:101 shown.

[0012] One of the objects of the present disclosure is to provide an anti-CD228 antibody or antigen-binding fragment, which comprises heavy chain and light chain variable regions, wherein the heavy chain and light chain variable regions comprise: HCDR1 as shown in SEQ ID NO: 54, HCDR2 as shown in TITX1X2GSYTYYPDNVKG, HCDR3 as shown in SEQ ID NO: 56, and LCDR1 as shown in X3ASQNVGTAVA, LCDR2 as shown in SEQ ID NO: 83 and LCDR3 as shown in SEQ ID NO: 84; wherein X1 is selected from D or E, X2 is selected from A or G, and X3 is selected from K, R, Q, W or S.

[0013] One of the objects of the present disclosure is to provide an anti-CD228 antibody or antigen-binding fragment, which comprises heavy chain and light chain variable regions, wherein the heavy chain and light chain variable regions comprise: HCDR1 as shown in SEQ ID NO: 54, HCDR2 as shown in SEQ ID NO: 55, HCDR3 as shown in SEQ ID NO: 56, and LCDR1 as shown in SEQ ID NO: 82, LCDR2 as shown in SEQ ID NO: 83, and LCDR3 as shown in SEQ ID NO: 84; or, HCDR1 as shown in SEQ ID NO: 54, HCDR2 as shown in SEQ ID NO: 177, HCDR3 as shown in SEQ ID NO: 56, and LCDR1 as shown in SEQ ID NO: 82, LCDR2 as shown in SEQ ID NO: 83, and LCDR3 as shown in SEQ ID NO: 84; or, HCDR1 as shown in SEQ ID NO: 54, HCDR2 as shown in SEQ ID NO: 178, HCDR3 as shown in SEQ ID NO: 56, and LCDR1 as shown in SEQ ID NO: 82, LCDR2 as shown in SEQ ID NO: 83, and LCDR3 as shown in SEQ ID NO: 84. NO:84; or, HCDR1 as set forth in SEQ ID NO:54, HCDR2 as set forth in SEQ ID NO:177, HCDR3 as set forth in SEQ ID NO:56, and LCDR1 as set forth in SEQ ID NO:180, LCDR2 as set forth in SEQ ID NO:83, and LCDR3 as set forth in SEQ ID NO:84; or, HCDR1 as set forth in SEQ ID NO:54, HCDR2 as set forth in SEQ ID NO:177, HCDR3 as set forth in SEQ ID NO:56, and LCDR1 as set forth in SEQ ID NO:181, LCDR2 as set forth in SEQ ID NO:83, and LCDR3 as set forth in SEQ ID NO:84; or, HCDR1 as set forth in SEQ ID NO:54, HCDR2 as set forth in SEQ ID NO:177, HCDR3 as set forth in SEQ ID NO:56, and LCDR1 as set forth in SEQ ID NO:182, LCDR2 as set forth in SEQ ID NO:83, and LCDR3 as set forth in SEQ ID NO:84; or, HCDR1 as set forth in SEQ ID NO:54, HCDR2 as set forth in SEQ ID NO:177, HCDR3 as set forth in SEQ ID NO:56, and LCDR1 as set forth in SEQ ID NO:182, LCDR2 as set forth in SEQ ID NO:83, and LCDR3 as set forth in SEQ ID NO:84 HCDR2 shown in SEQ ID NO:177, HCDR3 shown in SEQ ID NO:56, and LCDR1 shown in SEQ ID NO:183, LCDR2 shown in SEQ ID NO:83 and LCDR3 shown in SEQ ID NO:84.

[0014] One of the objects of the present disclosure is to provide an anti-CD228 antibody or antigen-binding fragment, which comprises heavy chain and light chain variable regions, wherein the heavy chain variable region sequence is as shown in SEQ ID NO: 129 or has at least 90%, 95%, 99% sequence identity thereto, and the light chain variable region sequence is as shown in SEQ ID NO: 111 or has at least 90%, 95%, 99% sequence identity thereto.

[0015] One of the objects of the present disclosure is to provide an anti-CD228 antibody or antigen-binding fragment, which comprises heavy chain and light chain variable regions, wherein the heavy chain variable region sequence is as shown in SEQ ID NO: 129 or has at least 90%, 95%, 99% sequence identity thereto, and the light chain variable region sequence is as shown in SEQ ID NO: 142 or has at least 90%, 95%, 99% sequence identity thereto.

[0016] One of the objects of the present disclosure is to provide an anti-CD228 antibody or antigen-binding fragment, which comprises heavy chain and light chain variable regions, wherein the heavy chain variable region sequence is as shown in SEQ ID NO: 129 or has at least 90%, 95%, 99% sequence identity thereto, and the light chain variable region sequence is as shown in SEQ ID NO: 143 or has at least 90%, 95%, 99% sequence identity thereto.

[0017] One of the objects of the present disclosure is to provide an anti-CD228 antibody or antigen-binding fragment, which comprises a heavy chain and a light chain variable region, wherein the heavy chain variable region sequence is as shown in SEQ ID NO: 129 or has at least 90%, 95%, 99% sequence identity thereto, and the light chain variable region sequence is as shown in SEQ ID NO: 144 or has at least 90%, 95%, 99% sequence identity thereto. One of the objects of the present disclosure is to provide an anti-CD228 antibody or antigen-binding fragment, which comprises a heavy chain and a light chain variable region, wherein the heavy chain variable region sequence is as shown in SEQ ID NO: 129 or has at least 90%, 95%, 99% sequence identity thereto, and the light chain variable region sequence is as shown in SEQ ID NO: 145 or has at least 90%, 95%, 99% sequence identity thereto.

[0018] One of the objects of the present disclosure is to provide an anti-CD228 antibody or antigen-binding fragment, which comprises heavy chain and light chain variable regions, wherein the heavy chain variable region is as shown in SEQ ID NO: 129, and the light chain variable region is as shown in SEQ ID NO: 111; or, wherein the heavy chain variable region is as shown in SEQ ID NO: 129, and the light chain variable region is as shown in SEQ ID NO: 142; or, wherein the heavy chain variable region is as shown in SEQ ID NO: 129, and the light chain variable region is as shown in SEQ ID NO: 143; or, wherein the heavy chain variable region is as shown in SEQ ID NO: 129, and the light chain variable region is as shown in SEQ ID NO: 144; or, wherein the heavy chain variable region is as shown in SEQ ID NO: 129, and the light chain variable region is as shown in SEQ ID NO: 145.

[0019] One of the objects of the present disclosure is to provide an anti-CD228 antibody or antigen-binding fragment, which comprises a heavy chain and a light chain variable region, wherein the heavy chain variable region is as shown in SEQ ID NO: 112, and the light chain variable region is as shown in SEQ ID NO: 115; or wherein the heavy chain variable region is as shown in SEQ ID NO: 112, and the light chain variable region is as shown in SEQ ID NO: 116; or wherein the heavy chain variable region is as shown in SEQ ID NO: 112, and the light chain variable region is as shown in SEQ ID NO: 117; or wherein the heavy chain variable region is as shown in SEQ ID NO: 112, and the light chain variable region is as shown in SEQ ID NO: 118; or wherein the heavy chain variable region is as shown in SEQ ID NO: 113, and the light chain variable region is as shown in SEQ ID NO: 115; or wherein the heavy chain variable region is as shown in SEQ ID NO: 113, and the light chain variable region is as shown in SEQ ID NO: 116; or wherein the heavy chain variable region is as shown in SEQ ID NO: 113, and the light chain variable region is as shown in SEQ ID NO: 117; or wherein the heavy chain variable region is as shown in SEQ ID NO: 113, and the light chain variable region is as shown in SEQ ID NO: 118; NO:113, and the light chain variable region is shown in SEQ ID NO:118; or wherein the heavy chain variable region is shown in SEQ ID NO:114, and the light chain variable region is shown in SEQ ID NO:115; or wherein the heavy chain variable region is shown in SEQ ID NO:114, and the light chain variable region is shown in SEQ ID NO:116; or wherein the heavy chain variable region is shown in SEQ ID NO:114, and the light chain variable region is shown in SEQ ID NO:117; or wherein the heavy chain variable region is shown in SEQ ID NO:114, and the light chain variable region is shown in SEQ ID NO:118; or wherein the heavy chain variable region is shown in SEQ ID NO:119, and the light chain variable region is shown in SEQ ID NO:118; or wherein the heavy chain variable region is shown in SEQ ID NO:120, and the light chain variable region is shown in SEQ ID NO:118; or wherein the heavy chain variable region is shown in SEQ ID NO:130, and the light chain variable region is shown in SEQ ID NO:118; or wherein the heavy chain variable region is shown in SEQ ID NO:131, and the light chain variable region is shown in SEQ ID NO:132; or wherein the heavy chain variable region is shown in SEQ ID NO:133, and the light chain variable region is shown in SEQ ID NO:134; or wherein the heavy chain variable region is shown in SEQ ID NO:135 NO:131, and the light chain variable region is shown in SEQ ID NO:118; or wherein the heavy chain variable region is shown in SEQ ID NO:132, and the light chain variable region is shown in SEQ ID NO:118; or wherein the heavy chain variable region is shown in SEQ ID NO:119, and the light chain variable region is shown in SEQ ID NO:133; or wherein the heavy chain variable region is shown in SEQ ID NO:130, and the light chain variable region is shown in SEQ ID NO:133; or wherein the heavy chain variable region is shown in SEQ ID NO:131, and the light chain variable region is shown in SEQ ID NO:133;or wherein the heavy chain variable region is as shown in SEQ ID NO: 132, and the light chain variable region is as shown in SEQ ID NO: 133. ;

[0020] One of the objects of the present disclosure is to provide an anti-CD228 antibody or antigen-binding fragment, which comprises heavy chain and light chain variable regions, wherein the heavy chain and light chain variable regions comprise: HCDR1 as shown in SEQ ID NO: 36, HCDR2 as shown in X1ITYX2GSNTYNPSLKX3, HCDR3 as shown in SYYGRGX4, and LCDR1 as shown in KASX5X6INNRLA, LCDR2 as shown in GX7X8SX9ET and LCDR3 as shown in QQYX10STPYT; wherein X1 is selected from Y or S; X2 is selected from D, E or S, selected from X3 is selected from N or S, X4 is selected from M or S, X5 is selected from Q, E, S or N, X6 is selected from D, S or N, X7 is selected from A or S, X8 is selected from T or S, X9 is selected from L or R, and X10 is selected from W or D.

[0021] One of the objects of the present disclosure is to provide an anti-CD228 antibody or antigen-binding fragment, which comprises heavy chain and light chain variable regions, wherein the heavy chain and light chain variable regions comprise: HCDR1 as shown in SEQ ID NO:36, HCDR2 as shown in SEQ ID NO:37, HCDR3 as shown in SEQ ID NO:38, and LCDR1 as shown in SEQ ID NO:66, LCDR2 as shown in SEQ ID NO:67, and LCDR3 as shown in SEQ ID NO:68; or, HCDR1 as shown in SEQ ID NO:36, HCDR2 as shown in SEQ ID NO:184, HCDR3 as shown in SEQ ID NO:38, and LCDR1 as shown in SEQ ID NO:66, LCDR2 as shown in SEQ ID NO:67, and LCDR3 as shown in SEQ ID NO:68; or, HCDR1 as shown in SEQ ID NO:36, HCDR2 as shown in SEQ ID NO:185, HCDR3 as shown in SEQ ID NO:38, and LCDR1 as shown in SEQ ID NO:66, LCDR2 as shown in SEQ ID NO:67, and LCDR3 as shown in SEQ ID NO:68. NO:68; or, HCDR1 as set forth in SEQ ID NO:36, HCDR2 as set forth in SEQ ID NO:37, HCDR3 as set forth in SEQ ID NO:186, and LCDR1 as set forth in SEQ ID NO:66, LCDR2 as set forth in SEQ ID NO:67, and LCDR3 as set forth in SEQ ID NO:68; or, HCDR1 as set forth in SEQ ID NO:36, HCDR2 as set forth in SEQ ID NO:37, HCDR3 as set forth in SEQ ID NO:38, and LCDR1 as set forth in SEQ ID NO:66, LCDR2 as set forth in SEQ ID NO:70, and LCDR3 as set forth in SEQ ID NO:68; or, HCDR1 as set forth in SEQ ID NO:36, HCDR2 as set forth in SEQ ID NO:187, HCDR3 as set forth in SEQ ID NO:38, and LCDR1 as set forth in SEQ ID NO:66, LCDR2 as set forth in SEQ ID NO:67, and LCDR3 as set forth in SEQ ID NO:68; or, HCDR1 as set forth in SEQ ID NO:36, HCDR2 as set forth in SEQ ID NO:37, HCDR3 as set forth in SEQ ID NO:38, and LCDR1 as set forth in SEQ ID NO:66, LCDR2 as set forth in SEQ ID NO:67, and LCDR3 as set forth in SEQ ID NO:68 HCDR2 shown in SEQ ID NO:37, HCDR3 shown in SEQ ID NO:38, and LCDR1 shown in SEQ ID NO:66, LCDR2 shown in SEQ ID NO:67, and LCDR3 shown in SEQ ID NO:189;or, HCDR1 as set forth in SEQ ID NO:36, HCDR2 as set forth in SEQ ID NO:188, HCDR3 as set forth in SEQ ID NO:38, and LCDR1 as set forth in SEQ ID NO:66, LCDR2 as set forth in SEQ ID NO:67, and LCDR3 as set forth in SEQ ID NO:68; or, HCDR1 as set forth in SEQ ID NO:36, HCDR2 as set forth in SEQ ID NO:184, HCDR3 as set forth in SEQ ID NO:38, and LCDR1 as set forth in SEQ ID NO:190, LCDR2 as set forth in SEQ ID NO:67, and LCDR3 as set forth in SEQ ID NO:68; or, HCDR1 as set forth in SEQ ID NO:36, HCDR2 as set forth in SEQ ID NO:184, HCDR3 as set forth in SEQ ID NO:38, and LCDR1 as set forth in SEQ ID NO:66, LCDR2 as set forth in SEQ ID NO:191, and LCDR3 as set forth in SEQ ID NO:68; or, HCDR1 as set forth in SEQ ID NO:36, HCDR2 as set forth in SEQ ID NO:184, HCDR3 as set forth in SEQ ID NO:38, and LCDR1 as set forth in SEQ ID NO:66, LCDR2 as set forth in SEQ ID NO:192, and LCDR3 as set forth in SEQ ID NO:68. NO:66, LCDR2 shown in SEQ ID NO:67, and LCDR3 shown in SEQ ID NO:68; or, HCDR1 shown in SEQ ID NO:36, HCDR2 shown in SEQ ID NO:184, HCDR3 shown in SEQ ID NO:38, and LCDR1 shown in SEQ ID NO:66, LCDR2 shown in SEQ ID NO:192, and LCDR3 shown in SEQ ID NO:68; or, HCDR1 shown in SEQ ID NO:36, HCDR2 shown in SEQ ID NO:184, HCDR3 shown in SEQ ID NO:186, and LCDR1 shown in SEQ ID NO:66, LCDR2 shown in SEQ ID NO:67, and LCDR3 shown in SEQ ID NO:68; or, HCDR1 shown in SEQ ID NO:36, HCDR2 shown in SEQ ID NO:184, HCDR3 shown in SEQ ID NO:38, and LCDR1 shown in SEQ ID NO:190, LCDR2 shown in SEQ ID NO:191, and LCDR3 shown in SEQ ID NO:192; LCDR2 shown in SEQ ID NO:67 and LCDR3 shown in SEQ ID NO:68;or, HCDR1 as set forth in SEQ ID NO:36, HCDR2 as set forth in SEQ ID NO:184, HCDR3 as set forth in SEQ ID NO:186, and LCDR1 as set forth in SEQ ID NO:190, LCDR2 as set forth in SEQ ID NO:67, and LCDR3 as set forth in SEQ ID NO:68; or, HCDR1 as set forth in SEQ ID NO:36, HCDR2 as set forth in SEQ ID NO:184, HCDR3 as set forth in SEQ ID NO:38, and LCDR1 as set forth in SEQ ID NO:193, LCDR2 as set forth in SEQ ID NO:67, and LCDR3 as set forth in SEQ ID NO:68; or, HCDR1 as set forth in SEQ ID NO:36, HCDR2 as set forth in SEQ ID NO:184, HCDR3 as set forth in SEQ ID NO:38, and LCDR1 as set forth in SEQ ID NO:194, LCDR2 as set forth in SEQ ID NO:67, and LCDR3 as set forth in SEQ ID NO:68; or, HCDR1 as set forth in SEQ ID NO:36, HCDR2 as set forth in SEQ ID NO:184, HCDR3 as set forth in SEQ ID NO:38, and LCDR1 as set forth in SEQ ID NO:194, LCDR2 as set forth in SEQ ID NO:67, and LCDR3 as set forth in SEQ ID NO:68. HCDR3 as shown in SEQ ID NO:38, and LCDR1 as shown in SEQ ID NO:195, LCDR2 as shown in SEQ ID NO:67, and LCDR3 as shown in SEQ ID NO:68; or, HCDR1 as shown in SEQ ID NO:36, HCDR2 as shown in SEQ ID NO:184, HCDR3 as shown in SEQ ID NO:38, and LCDR1 as shown in SEQ ID NO:196, LCDR2 as shown in SEQ ID NO:67, and LCDR3 as shown in SEQ ID NO:68.;

[0022] One of the objects of the present disclosure is to provide an anti-CD228 antibody or antigen-binding fragment, which comprises heavy chain and light chain variable regions, wherein the heavy chain variable region sequence is as shown in SEQ ID NO: 157 or has at least 90%, 95%, 99% sequence identity thereto, and the light chain variable region sequence is as shown in SEQ ID NO: 168 or has at least 90%, 95%, 99% sequence identity thereto.

[0023] One of the objects of the present disclosure is to provide an anti-CD228 antibody or antigen-binding fragment, which comprises a heavy chain and a light chain variable region, wherein the heavy chain variable region is as shown in SEQ ID NO: 146, and the light chain variable region is as shown in SEQ ID NO: 126; or wherein the heavy chain variable region is as shown in SEQ ID NO: 147, and the light chain variable region is as shown in SEQ ID NO: 126; or wherein the heavy chain variable region is as shown in SEQ ID NO: 148, and the light chain variable region is as shown in SEQ ID NO: 126; or wherein the heavy chain variable region is as shown in SEQ ID NO: 149, and the light chain variable region is as shown in SEQ ID NO: 126; or wherein the heavy chain variable region is as shown in SEQ ID NO: 150, and the light chain variable region is as shown in SEQ ID NO: 126; or wherein the heavy chain variable region is as shown in SEQ ID NO: 151, and the light chain variable region is as shown in SEQ ID NO: 160; or wherein the heavy chain variable region is as shown in SEQ ID NO: 152, and the light chain variable region is as shown in SEQ ID NO: 126; or wherein the heavy chain variable region is as shown in SEQ ID NO: 153. NO:151, and the light chain variable region is shown in SEQ ID NO:161; or wherein the heavy chain variable region is shown in SEQ ID NO:153, and the light chain variable region is shown in SEQ ID NO:126; or wherein the heavy chain variable region is shown in SEQ ID NO:154, and the light chain variable region is shown in SEQ ID NO:126; or wherein the heavy chain variable region is shown in SEQ ID NO:151, and the light chain variable region is shown in SEQ ID NO:162; or wherein the heavy chain variable region is shown in SEQ ID NO:155, and the light chain variable region is shown in SEQ ID NO:126; or wherein the heavy chain variable region is shown in SEQ ID NO:147, and the light chain variable region is shown in SEQ ID NO:163; or wherein the heavy chain variable region is shown in SEQ ID NO:147, and the light chain variable region is shown in SEQ ID NO:164; or wherein the heavy chain variable region is shown in SEQ ID NO:147, and the light chain variable region is shown in SEQ ID NO:165; or wherein the heavy chain variable region is shown in SEQ ID NO:147. NO:147, and the light chain variable region is shown in SEQ ID NO:166; or wherein the heavy chain variable region is shown in SEQ ID NO:147, and the light chain variable region is shown in SEQ ID NO:167; or wherein the heavy chain variable region is shown in SEQ ID NO:156, and the light chain variable region is shown in SEQ ID NO:126; or wherein the heavy chain variable region is shown in SEQ ID NO:157, and the light chain variable region is shown in SEQ ID NO:126; or wherein the heavy chain variable region is shown in SEQ ID NO:156, and the light chain variable region is shown in SEQ ID NO:168;or wherein the heavy chain variable region is as shown in SEQ ID NO: 159, and the light chain variable region is as shown in SEQ ID NO: 126; or wherein the heavy chain variable region is as shown in SEQ ID NO: 156, and the light chain variable region is as shown in SEQ ID NO: 166; or wherein the heavy chain variable region is as shown in SEQ ID NO: 156, and the light chain variable region is as shown in SEQ ID NO: 169; or wherein the heavy chain variable region is as shown in SEQ ID NO: 156, and the light chain variable region is as shown in SEQ ID NO: 170; or wherein the heavy chain variable region is as shown in SEQ ID NO: 157, and the light chain variable region is as shown in SEQ ID NO: 168; or wherein the heavy chain variable region is as shown in SEQ ID NO: 157, and the light chain variable region is as shown in SEQ ID NO: 169; or wherein the heavy chain variable region is as shown in SEQ ID NO: 156, and the light chain variable region is as shown in SEQ ID NO: 171; or wherein the heavy chain variable region is as shown in SEQ ID NO: 156, and the light chain variable region is as shown in SEQ ID NO: 172. ID NO: 172; or wherein the heavy chain variable region is as shown in SEQ ID NO: 156, and the light chain variable region is as shown in SEQ ID NO: 173; or wherein the heavy chain variable region is as shown in SEQ ID NO: 156, and the light chain variable region is as shown in SEQ ID NO: 174; or wherein the heavy chain variable region is as shown in SEQ ID NO: 156, and the light chain variable region is as shown in SEQ ID NO: 175; or wherein the heavy chain variable region is as shown in SEQ ID NO: 156, and the light chain variable region is as shown in SEQ ID NO: 176; or wherein the heavy chain variable region is as shown in SEQ ID NO: 157, and the light chain variable region is as shown in SEQ ID NO: 176; or wherein the heavy chain variable region is as shown in SEQ ID NO: 158, and the light chain variable region is as shown in SEQ ID NO: 176. ;

[0024] In some embodiments of the present disclosure, an anti-CD228 antibody or antigen-binding fragment as described above is provided, wherein the antigen-binding fragment is selected from Fab, Fab', F(ab')2, single-chain antibody (scFv), single-domain antibody (sdAb), dimerized V region (diabody), disulfide bond-stabilized V region (dsFv) and an antigen-binding fragment of a peptide comprising CDR.

[0025] In some embodiments of the present disclosure, an anti-CD228 antibody or an antigen-binding fragment thereof as described above is provided, which comprises an antibody constant region; wherein the heavy chain constant region is derived from human IgG1, IgG2, IgG3 or IgG4 or a variant thereof; and / or the light chain constant region is derived from human antibody κ, λ chain or a variant thereof; preferably, the amino acid sequence of the heavy chain constant region is derived from human IgG1 or a variant thereof; and / or the light chain constant region is derived from human antibody κ chain or a variant thereof; more preferably, the amino acid sequence of the heavy chain constant region is as shown in SEQ ID NO: 134, and the amino acid sequence of the light chain constant region is as shown in SEQ ID NO: 135.

[0026] In some embodiments of the present disclosure, an anti-CD228 antibody or an antigen-binding fragment thereof as described above is provided, which comprises an antibody constant region; wherein the heavy chain constant region is derived from human IgG1, IgG2, IgG3 or IgG4 or has at least 95% sequence identity therewith; and / or the light chain constant region is derived from human antibody κ, λ chain or has at least 95% sequence identity therewith; preferably, the amino acid sequence of the heavy chain constant region is derived from human IgG1 or has at least 95% sequence identity therewith; more preferably, the amino acid sequence of the heavy chain constant region is as shown in SEQ ID NO: 134, and the amino acid sequence of the light chain constant region is as shown in SEQ ID NO: 135.

[0027] In some embodiments of the present disclosure, an anti-CD228 antibody or an antigen-binding fragment thereof as described above is provided, which comprises: (1) a heavy chain sequence shown by SEQ ID NO: 197 and a light chain sequence shown by SEQ ID NO: 198; or (2) a heavy chain sequence shown by SEQ ID NO: 197 and a light chain sequence shown by SEQ ID NO: 199; or (3) a heavy chain sequence shown by SEQ ID NO: 200 and a light chain sequence shown by SEQ ID NO: 201.

[0028] In another aspect, the present disclosure provides an isolated anti-CD228 antibody or antigen-binding fragment thereof that competes with any of the aforementioned antibodies or antigen-binding fragments thereof for binding to CD228.

[0029] Polynucleotides and vectors

[0030] The present disclosure provides isolated polynucleotides encoding the anti-CD228 antibodies or antigen-binding fragments thereof of the present disclosure. The polynucleotides may be DNA or RNA. The present disclosure provides expression vectors containing the polynucleotides as described above, which may be eukaryotic expression vectors, prokaryotic expression vectors, viral vectors, such as plasmids, cosmids, and bacteriophages.

[0031] In another aspect, the present invention discloses an isolated nucleic acid encoding any of the aforementioned anti-CD228 antibodies or antigen-binding fragments thereof.

[0032] In another aspect, the present invention discloses a vector comprising the nucleic acid as described above.

[0033] Host cells

[0034] In yet another aspect, the present disclosure provides a host cell comprising the vector as described above.

[0035] The present disclosure provides a host cell transformed with an expression vector as described above, which can be a eukaryotic cell or a prokaryotic cell. In some embodiments, the host cell is a bacterium, a yeast, or a mammalian cell. In some specific embodiments, the host cell is an Escherichia coli, a Pichia pastoris, a Chinese hamster ovary (CHO) cell, or a human embryonic kidney (HEK) 293 cell.

[0036] Preparation method

[0037] In one aspect, the present disclosure provides a method for preparing an anti-CD228 antibody or an antigen-binding fragment thereof, comprising culturing the aforementioned host cell under conditions suitable for expressing the anti-CD228 antibody or the antigen-binding fragment thereof.

[0038] The present disclosure provides a method for preparing an anti-CD228 antibody or an antigen-binding fragment thereof, comprising: expressing the antibody or its antigen-binding fragment in a host cell as described above, and isolating the antibody or its antigen-binding fragment from the host cell. Optionally, a purification step may also be included, for example, purification using an A or G Sepharose FF column containing an adjusted buffer, washing away non-specifically bound components, eluting the bound antibody using a pH gradient method, detecting with SDS-PAGE, and collecting. Optionally, filtration and concentration are performed using conventional methods. Soluble mixtures and polymers may also be removed using conventional methods, such as molecular sieves and ion exchange. The obtained product needs to be immediately frozen, such as at -70°C, or freeze-dried.

[0039] Methods for producing and purifying antibodies and antigen-binding fragments are well known and can be found in the prior art, such as the Cold Spring Harbor Manual of Antibody Laboratory Techniques (Chapters 5-8 and 15). For example, mice can be immunized with human FcRn or fragments thereof, and the resulting antibodies can be renatured, purified, and amino acid sequenced using conventional methods. Antigen-binding fragments can also be prepared using conventional methods.

[0040] The engineered antibodies or antigen-binding fragments disclosed herein can be prepared and purified by conventional methods. For example, cDNA sequences encoding heavy and light chains can be cloned and recombined into expression vectors. The recombinant immunoglobulin expression vector can stably transfect CHO cells. Mammalian expression systems can lead to glycosylation of antibodies, especially at the highly conserved N-terminus of the Fc region. Stable clones are obtained by expressing antibodies that specifically bind to human antigens. Positive clones are expanded and cultured in serum-free culture medium in a bioreactor to produce antibodies. The culture fluid that secretes antibodies can be purified and collected by conventional techniques. Antibodies can be filtered and concentrated by conventional methods. Soluble mixtures and polymers can also be removed by conventional methods, such as molecular sieves and ion exchange.

[0041] Conjugates of anti-CD228 antibodies or antigen-binding fragments and drugs

[0042] In one aspect, the present disclosure provides an antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, comprising the anti-CD228 antibody or antigen-binding fragment thereof as described in any of the preceding items.

[0043] In some embodiments, the aforementioned antibody-drug conjugate or its pharmaceutically acceptable salt or solvate, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, wherein the drug is selected from cytotoxic agents, radioactive markers, fluorophores, chromophores, imaging agents, immunomodulators, angiogenesis inhibitors, cell proliferation inhibitors, pro-apoptotic agents, cell lytic enzymes, and any combination thereof; preferably, the drug is selected from: DNA damaging agents, topoisomerase inhibitors, microtubule inhibitors, protein degraders, STING agonists, and any combination thereof.

[0044] In some embodiments, the aforementioned antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof,

[0045] It has a structure shown in general formula (I):

[0046] Pc-(LY-Dr) n

[0047] (I)

[0048] Wherein, Dr is the aforementioned drug;

[0049] Preferably, Dr is selected from the group consisting of camptothecin, auristatin, maytansinoid, vinca alkaloid, pyrrolobenzodiazepine (PBD), calicheamicin, duocarmycin, daunorubicin, doxorubicin, calicheamicin, anthramycin, neomycin, amatoxin, hemipteratin, eribulin, Tubulysin, and analogs or derivatives thereof;

[0050] More preferably, Dr is selected from: Exatecan, MMAE, MMAF, MMAD, SN-38, DM1, DM4, pyrrolebenzodiazepine (PBD) dimer, and analogs or derivatives thereof; n is 1 to 10, preferably n is 2 to 8, more preferably n is 3 to 5 or 4 to 8, n is a decimal or an integer, further preferably, n is 2, 4, 6, 8;

[0051] L and Y are joint units;

[0052] Pc is any of the aforementioned anti-CD228 antibodies or antigen-binding fragments thereof.

[0053] In some embodiments, the aforementioned antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, has a structure represented by the general formula (Pc-LY-Dr), general formula (II), general formula (III), or general formula (IV):

[0054]

[0055] Wherein: Y is selected from -O-(CR a R b ) m -CR 1 R 2 -C(O)-, -O-CR 1 R 2 -(CR a R b ) m -、-O-CR 1 R 2 -、-NH-(CR a R b ) m -CR 1 R 2 -C(O)- or -S-(CR a R b ) m -CR 1 R 2 -C(O)-; R a and R bare the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, an alkyl group, a haloalkyl group, a deuterated alkyl group, an alkoxy group, a hydroxyl group, an amino group, a cyano group, a nitro group, a hydroxyalkyl group, a cycloalkyl group or a heterocyclic group; or, R a and R b Together with the carbon atom to which it is attached, it forms a cycloalkyl or heterocyclic group; R 1 R is selected from halogen, haloalkyl, deuterated alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, heterocyclyl, aryl or heteroaryl; 2 is selected from hydrogen, halogen, haloalkyl, deuterated alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, heterocyclic, aryl or heteroaryl; or, R 1 and R 2 Together with the carbon atom to which it is attached, it forms a cycloalkyl or heterocyclic group; or, R a and R 2 Together with the carbon atom connected thereto, it forms a cycloalkyl group or a heterocyclic group; m is an integer from 0 to 4; n is from 1 to 10, n is a decimal or an integer, preferably n is from 2 to 8, more preferably n is from 3 to 5 or from 4 to 8, n is a decimal or an integer, further preferably, n is 2, 4, 6, 8; L is a linker unit; Pc is an anti-CD228 antibody or an antigen-binding fragment thereof as described in any of the preceding items.

[0056] In some embodiments of the present disclosure, an antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof is provided, wherein n is 2 to 8, preferably 3 to 8, more preferably 3 to 5 or 4 to 8, and n is a decimal or an integer, and further preferably, n is 2, 4, 6, or 8.

[0057] In some embodiments of the present disclosure, the aforementioned antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, wherein: Y is -O-(CR a R b ) m -CR 1 R 2 -C(O)-; R a and R b are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen or an alkyl group; R 1 is a halogenated alkyl or C 3-6 Cycloalkyl; R 2 is selected from a hydrogen atom, a haloalkyl group or a C 3-6 Cycloalkyl; or, R 1 and R 2 Together with the carbon atom to which it is attached, it forms C 3-6 Cycloalkyl; m is 0 or 1.

[0058] In some embodiments of the present disclosure, the aforementioned antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, wherein Y is selected from:

[0059]

[0060] In some embodiments of the present disclosure, the aforementioned antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, wherein the O end of Y is connected to the linker unit L.

[0061] In some embodiments of the present disclosure, the aforementioned antibody-drug conjugate or its pharmaceutically acceptable salt or solvate, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, wherein the linker unit -L- is -L 1 -L 2 -L 3 -L 4 -, L 1 for s 1 is an integer from 2 to 8; L 2 is a chemical bond; L 3 is a tetrapeptide residue; L 4 For-NR 5 (CR 6 R 7 )t-,R 5 , R 6 or R 7 are the same or different and are each independently a hydrogen atom or an alkyl group, and t is 1 or 2.

[0062] In some embodiments of the present disclosure, the aforementioned antibody-drug conjugate or its pharmaceutically acceptable salt or solvate, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, wherein the linker unit -L- is -L 1 -L 2 -L 3 -L 4 -, L 1 for s 1 and 2 independently selected from integers from 0 to 8; preferably s 1 is 2, s 2 is an integer from 2 to 8; more preferably, s 1 is 2, s 2 2, 3, 4, 5 or 6; L2 is a chemical bond; L 3 is a tetrapeptide residue; L 4 For-NR 5 (CR 6 R 7 )t-,R 5 , R 6 or R 7 are the same or different and are each independently a hydrogen atom or an alkyl group, and t is 1 or 2.

[0063] In some embodiments of the present disclosure, the aforementioned antibody-drug conjugate or its pharmaceutically acceptable salt or solvate, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, wherein the linker unit -L-, wherein L 1 The end is connected to Pc, L 4 Connect the Y end.

[0064] In some embodiments of the present disclosure, the aforementioned antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, wherein the L 3 The tetrapeptide residue is an amino acid residue formed by two or more amino acids selected from phenylalanine, glycine, valine, lysine, citrulline, serine, glutamic acid, and aspartic acid; preferably, the tetrapeptide residue is GGFG.

[0065] In some embodiments of the present disclosure, the aforementioned antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, wherein the -LY- is the following structure:

[0066]

[0067] L 2 is a chemical bond; L 3 is the tetrapeptide residue of GGFG; R 1 is a halogenated alkyl or C 3-6 Cycloalkyl; R 2 is selected from a hydrogen atom, a haloalkyl group or a C 3-6 Cycloalkyl; or, R 1 and R 2 Together with the carbon atom to which it is attached, it forms C 3-6 Cycloalkyl; R 5 , R 6 or R 7 are the same or different and are each independently a hydrogen atom or an alkyl group; 1 is an integer from 2 to 8; m is an integer from 0 to 4.

[0068] In some embodiments of the present disclosure, the aforementioned antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, wherein -LY- is selected from:

[0069]

[0070]

[0071] In some embodiments of the present disclosure, the antibody-drug conjugate represented by the general formula (Pc-LY-Dr) or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, which is a general formula (Pc-L a -Y-Dr) or a pharmaceutically acceptable salt or solvate thereof:

[0072]

[0073] Where: W is selected from C 1-8 Alkyl, C 1-8 Alkyl-cycloalkyl or straight chain heteroalkyl of 1 to 8 atoms, the heteroalkyl containing 1 to 3 heteroatoms selected from N, O or S, wherein the C 1-8 Alkyl, cycloalkyl and straight-chain heteroalkyl are each independently optionally further substituted with one or more substituents selected from halogen, hydroxy, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl; L 2 Selected from -NR 4 (CH2CH2O) p1 CH2CH2C(O)-、-NR 4 (CH2CH2O) p1 CH2C(O)-、-S(CH2) p1 C(O)- or chemical bond, p 1 is an integer from 1 to 20; L 3 is a peptide residue consisting of 2 to 7 amino acids, the amino acids may be substituted or unsubstituted, and when substituted, the substituent may be substituted at any available attachment point, the substituent being one or more independently selected from halogen, hydroxyl, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl; R 1 R is selected from halogen, haloalkyl, deuterated alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl; 2 is selected from hydrogen, halogen, haloalkyl, deuterated alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl; or, R 1 and R2 Together with the carbon atom to which it is attached, it forms a cycloalkyl or heterocyclic group; R 4 and R 5 are the same or different and are each independently selected from a hydrogen atom, an alkyl group, a halogenated alkyl group, a deuterated alkyl group and a hydroxyalkyl group; R 6 and R 7 are the same or different and are each independently selected from a hydrogen atom, a halogen, an alkyl group, a halogenated alkyl group, a deuterated alkyl group and a hydroxyalkyl group; m is an integer from 0 to 4; n is 1 to 10, and n is a decimal or an integer; Pc is an anti-CD228 antibody or an antigen-binding fragment thereof as described in any of the preceding items.

[0074] In some embodiments of the present disclosure, the antibody-drug conjugate represented by the general formula (Pc-LY-Dr) or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, which is a general formula (Pc-L b -Y-Dr) or a pharmaceutically acceptable salt or solvate thereof:

[0075]

[0076] Where: s 1 is an integer from 2 to 8; R 1 , R 2 , R 5 ~R 7 , m and n are as defined in the general formula (Pc-La-Y-Dr).

[0077] In some embodiments of the present disclosure, the aforementioned antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, the antibody-drug conjugate is selected from:

[0078]

[0079]

[0080]

[0081]

[0082]

[0083]

[0084]

[0085]

[0086] wherein Pc is as defined above;

[0087] n is 1 to 10, n is a decimal or an integer, preferably n is 2 to 8, more preferably n is 3 to 5 or 4 to 8, n is a decimal or an integer, further preferably, n is 2, 4, 6, 8.

[0088] Typical antibody-drug conjugates disclosed herein include, but are not limited to:

[0089]

[0090]

[0091]

[0092] Wherein n can be a non-zero integer or decimal from 0 to 10, preferably an integer or decimal between 1-10; more preferably, it is from 2 to 8, which can be an integer or a decimal; further preferably, it is from 3 to 8, which can be an integer or a decimal; further preferably, n is 2, 4, 6, or 8.

[0093] The present disclosure further provides a method for preparing a method of preparing a a -Y-Dr) or a pharmaceutically acceptable salt or solvate thereof, comprising the following steps:

[0094]

[0095] After Pc reduction, it is combined with the general formula (L a -Y-Dr) coupling reaction to obtain the general formula (Pc-L a -Y-Dr) as shown in the compound; wherein: Pc is an anti-CD228 antibody or an antigen-binding fragment thereof as described in any of the preceding items; W, L 2 , L 3 , R 1 , R 2 , R 5 ~R 7 , m and n are as in the general formula (Pc-L a -Y-Dr) as defined.

[0096] In another embodiment, another method is provided, wherein the general formula L a -Y-Dr is the general formula L b -Y-Dr represented by the compound:

[0097]

[0098] or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 5 ~R 7 、s 1 and m as the general formula Pc-L b -Y-As defined in Dr.

[0099] In a preferred embodiment of the present disclosure, according to the general formula (Pc-L a -Y-Dr) or general formula (Pc-L b -Y-Dr) or a pharmaceutically acceptable salt or solvate thereof, wherein the general formula (L a -Y-Dr) or a compound represented by the general formula (L b -Y-Dr) is selected from:

[0100]

[0101]

[0102] On the other hand, the present disclosure provides a kit comprising the anti-CD228 antibody or antigen-binding fragment thereof according to any one of claims 1 to 7, or the antibody-drug conjugate or pharmaceutically acceptable salt or solvate thereof according to any one of claims 12 to 23, or a tautomer, mesoform, racemate, enantiomer, diastereomer, or a mixture thereof.

[0103] On the other hand, the present disclosure provides a pharmaceutical composition comprising the anti-CD228 antibody or antigen-binding fragment thereof according to the present disclosure, or the antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof according to the present disclosure, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, and one or more pharmaceutically acceptable carriers.

[0104] On the other hand, the present disclosure provides the use of the anti-CD228 antibody or antigen-binding fragment thereof according to the present disclosure, the antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutical composition comprising the same in the preparation of a medicament for treating a disease or condition mediated by CD228, wherein the disease or condition mediated by CD228 is a CD228-expressing cancer.

[0105] On the other hand, the present disclosure provides the use of the anti-CD228 antibody or antigen-binding fragment thereof according to the present disclosure, the antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, or a pharmaceutical composition comprising the same in the preparation of a medicament for treating or preventing a tumor or cancer; wherein the cancer is preferably: melanoma, pancreatic cancer, mesothelioma, colorectal cancer, lung cancer, thyroid cancer, breast cancer, bile duct cancer, esophageal cancer and head and neck cancer.

[0106] The active compound may be formulated for administration by any appropriate route, preferably in a unit dosage form, or in a form in which a patient can self-administer a single dose. The unit dosage form of the disclosed compound or composition may be tablets, capsules, cachets, bottled liquids, powders, granules, lozenges, suppositories, reconstituted powders or liquid preparations.

[0107] The dosage of the compound or composition used in the disclosed treatment methods will generally vary with the severity of the disease, the patient's weight and the relative efficacy of the compound. However, as a general guide, a suitable unit dosage may be 0.1 to 1000 mg.

[0108] The pharmaceutical composition of the present disclosure may contain one or more excipients in addition to the active compound, and the excipients are selected from the following ingredients: fillers (diluents), binders, wetting agents, disintegrants or excipients, etc. Depending on the administration method, the composition may contain 0.1 to 99% by weight of the active compound. BRIEF DESCRIPTION OF THE DRAWINGS

[0109] Figure 1 shows the internalization activity of CD228 antibody on A2058, SK-MEL-28, MDA-MB-231, and DLD-1 cells. Figure 1A For A2058 cells, Figure 1B For SK-MEL-28 cells, Figure 1C For MDA-MB-231 cells, Figure 1D These are DLD-1 cells.

[0110] Figure 2 shows the anti-tumor activity results of ADC in the A2058 cell xenograft model, where: Figure 2A The change of mouse tumor volume. Figure 2B The figure shows the changes in mouse body weight.

[0111] FIG3 shows the anti-tumor activity results of ADC in the MDA-MB-231 cell xenograft model, where: Figure 3A The change of mouse tumor volume. Figure 3B The figure shows the changes in mouse body weight.

[0112] Figure 4 is a correlation analysis of the antigen expression and killing activity of DAR8 molecules on different tumor cells. Figure 4A 4B is the correlation analysis between the killing activity of HuPR003M25-9106 DAR8 on tumor cells and the antigen expression level, 4C is the correlation analysis between the killing activity of BMK1-MMAE DAR8 on tumor cells and the antigen expression level.

[0113] Figure 5 is a comparison of the in vivo efficacy of HuPR003M25-9106 DAR4, HuPR003M25-9106 DAR8 and PR0108M3-9106 DAR8 in the A2058 transplanted tumor model. Figure 5A The change of mouse tumor volume. Figure 5B The figure shows the changes in mouse body weight.

[0114] Figure 6 is a comparison of the in vivo efficacy of HuPR003M25-9106 DAR4, HuPR003M25-9106 DAR8 and PR0108M3-9106 DAR8 in the MDA-MB-231 xenograft tumor model. Figure 6A The change of mouse tumor volume. Figure 6B The figure shows the changes in mouse body weight.

[0115] Figure 7 These are the PK test results of HuPR003M25-9106 DAR8 and PR0108M3-9106 DAR8 in mice.

[0116] Detailed description of the invention

[0117] 1. Terminology

[0118] Unless otherwise defined, all technical and scientific terms used herein are consistent with the common understanding of one of ordinary skill in the art to which the present disclosure belongs. Although any methods and materials similar or equivalent to those described herein may be used to implement or test the present disclosure, preferred methods and materials are described herein. When describing and claiming the present disclosure, the following terms are used in accordance with the following definitions.

[0119] When a trade name is used in this disclosure, Applicants intend to include formulations of the trade name product, generic drugs, and the active drug portion of the trade name product.

[0120] Unless stated otherwise, the terms used in the specification and claims have the following meanings.

[0121] CD228, also known as Melanotransferrin / MFI2, has a gene located in the transferrin superfamily region of chromosome 3 and has similar sequences to members of the transferrin superfamily. CD228 is highly expressed in melanoma, breast cancer, pancreatic cancer, non-small cell lung cancer, colorectal cancer, and mesothelioma. Its C-terminus can react with glycosylphosphatidylinositol (GPI) and anchor to the cell membrane. It is a glycoprotein on the cell surface. CD228 contains two transferrin-like domains and can form two splicing bodies: full-length sequence splicing body 1 and splicing body 2 lacking the proximal transferrin-like domain 2. Splicing body 2 lacks transferrin-like domain 2 and cannot react with glycosylphosphatidylinositol to anchor to the cell membrane, and is free outside the cell. Because its sequence has certain similarities with transferrin, it is believed to be related to the uptake of iron ions. In addition, CD228 also has the characteristics of endocytosis and circulation to the cell membrane. Taking advantage of these properties, CD228 has been used as a target for anti-tumor drugs to develop antibody-drug conjugates.

[0122] The term "drug" refers to cytotoxic drugs, which are represented by Dr. They are chemical molecules that have a strong ability to destroy the normal growth of tumor cells. Cytotoxic drugs can kill tumor cells in principle at sufficiently high concentrations, but due to the lack of specificity, while killing tumor cells, they can also cause apoptosis of normal cells, leading to serious side effects. The term includes toxins, such as small molecule toxins or enzyme-active toxins from bacteria, fungi, plants or animals, radioactive isotopes (such as At 211 ,I 131 ,I 125 , Y 90 、Re 186 、Re 188 、Sm 153 、Bi 212 , P 32 and radioactive isotopes of Lu), toxic drugs, chemotherapeutic drugs, antibiotics and nucleolytic enzymes, preferably toxic drugs.

[0123] The term "linker unit (or linker fragment)" refers to a chemical structure fragment or bond that is connected to a ligand at one end and to a drug at the other end, and can also be connected to other linkers before being connected to a drug. 1 To L 4 , where L 1 The end is connected to the ligand, L 4 The end is connected to the structural unit Y and then connected to the drug (Dr).

[0124] The linker, including the extension, the spacer and the amino acid unit, can be synthesized by methods known in the art, such as those described in US2005-0238649A1. The linker can be a "cleavable linker" that facilitates the release of the drug in the cell. For example, an acid-labile linker (e.g., a hydrazone), a protease-sensitive (e.g., a peptidase-sensitive) linker, a photolabile linker, a dimethyl linker, or a disulfide-containing linker can be used (Chari et al., Cancer Research 52: 127-131 (1992); U.S. Patent No. 5,208,020).

[0125] The term "ligand-drug conjugate" refers to a ligand connected to a biologically active drug via a stable linker. In the present disclosure, "ligand-drug conjugate" is preferably an antibody-drug conjugate (ADC), which refers to a monoclonal antibody or antibody fragment connected to a biologically active toxic drug via a stable linker.

[0126] The three letter codes and one letter codes for amino acids used in this disclosure are as described in J. biol. chem, 243, p3558 (1968).

[0127] The term "antibody" refers to immunoglobulin, which is a tetrapeptide chain structure composed of two identical heavy chains and two identical light chains connected by interchain disulfide bonds. The amino acid composition and arrangement order of the constant region of the immunoglobulin heavy chain are different, so their antigenicity is also different. Based on this, immunoglobulins can be divided into five categories, or immunoglobulin isotypes, namely IgM, IgD, IgG, IgA and IgE, and their corresponding heavy chains are μ chain, δ chain, γ chain, α chain, and ε chain respectively. The same class of Ig can be divided into different subclasses according to the difference in the amino acid composition of its hinge region and the number and position of disulfide bonds in the heavy chain, such as IgG can be divided into IgG1, IgG2, IgG3, and IgG4. Light chains are divided into κ chains or λ chains according to the difference in constant regions. Each of the five classes of Ig can have κ chains or λ chains.

[0128] The sequences of about 110 amino acids near the N-terminus of the antibody heavy and light chains vary greatly, which is the variable region (Fv region); the remaining amino acid sequences near the C-terminus are relatively stable, which is the constant region. The variable region includes three hypervariable regions (HVRs) and four relatively conservative framework regions (FRs). The three hypervariable regions determine the specificity of the antibody, also known as the complementarity determining regions (CDRs). Each light chain variable region (LCVR) and heavy chain variable region (HCVR) consists of three CDR regions and four FR regions, arranged in the order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The three CDR regions of the light chain refer to LCDR1, LCDR2, and LCDR3; the three CDR regions of the heavy chain refer to HCDR1, HCDR2, and HCDR3. The number and position of the CDR amino acid residues in the LCVR and HCVR regions of the antibodies or antigen-binding fragments described in the present disclosure conform to the known Kabat numbering convention (LCDR1-3, HCDR2-3), or conform to the numbering convention of Kabat and Chothia (HCDR1).

[0129] The term "fully human antibody" or "fully human antibody", also known as "fully human monoclonal antibody", has both human variable and constant regions, eliminating immunogenicity and toxic side effects. The development of monoclonal antibodies has gone through four stages, namely: mouse monoclonal antibodies, chimeric monoclonal antibodies, humanized monoclonal antibodies and fully human monoclonal antibodies. The relevant technologies for the preparation of fully human antibodies mainly include: human hybridoma technology, EBV-transformed B lymphocyte technology, phage display technology (phage display), transgenic mouse antibody preparation technology (transgenic mouse) and single B cell antibody preparation technology, etc. The "fully human antibody" in the present disclosure is obtained using phage display technology. Phage display technology separates B cells from human PBMC, spleen, and lymph node tissues, constructs a natural single-chain phage human antibody library, or screens the obtained antibodies by immunizing transgenic mice that can express light and heavy chains of human antibodies.

[0130] The term "antigen-binding fragment" refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen. It has been shown that fragments of full-length antibodies can be used to perform the antigen-binding function of an antibody. Examples of binding fragments included in "antigen-binding fragments" include: (i) Fab fragments, monovalent fragments consisting of VL, VH, CL and CH1 domains; (ii) F(ab')2 fragments, bivalent fragments comprising two Fab fragments connected by a disulfide bridge on the hinge region; (iii) Fd fragments consisting of VH and CH1 domains; (iv) Fv fragments consisting of the VH and VL domains of a single arm of an antibody; (v) single domain or dAb fragments (Ward et al., (1989) Nature 341: 544-546), which consist of VHH domains; and (vi) isolated complementarity determining regions (CDRs) or (vii) combinations of two or more isolated CDRs, optionally connected by synthetic linkers. In addition, although the two domains VL and VH of the Fv fragment are encoded by separate genes, they can be connected by synthetic linkers using recombinant methods, so that they can be produced as a single protein chain in which the VL and VH regions are paired to form a monovalent molecule (called single-chain Fv (scFv); see, for example, Bird et al. (1988) Science 242: 423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci USA 85: 5879-5883). Such single-chain antibodies are also intended to be included in the term "antigen-binding fragment" of an antibody. Such antibody fragments are obtained using conventional techniques known to those skilled in the art, and the fragments are screened for functionality in the same manner as for intact antibodies. Antigen-binding portions can be produced by recombinant DNA technology or by enzymatic or chemical cleavage of intact immunoglobulins. The antibodies can be of different isotypes, for example, IgG (eg, IgG1, IgG2, IgG3 or IgG4 subtype), IgA1, IgA2, IgD, IgE or IgM antibodies.

[0131] Fab is an antibody fragment having a molecular weight of about 50,000 and having antigen-binding activity, among fragments obtained by treating IgG antibody molecules with the protease papain (cleaving the amino acid residue at position 224 of the H chain), in which about half of the N-terminal side of the H chain and the entire L chain are bound together by a disulfide bond.

[0132] F(ab')2 is an antibody fragment having a molecular weight of about 100,000 and antigen-binding activity, obtained by digesting the portion below two disulfide bonds in the hinge region of IgG with the enzyme pepsin, and comprising two Fab regions linked at the hinge position.

[0133] Fab' is an antibody fragment having a molecular weight of about 50,000 and having antigen-binding activity obtained by cleaving the disulfide bond of the hinge region of the above-mentioned F(ab')2.

[0134] Furthermore, the Fab' fragment of the antibody can be produced by inserting a DNA encoding the Fab' fragment into a prokaryotic expression vector or a eukaryotic expression vector and introducing the vector into a prokaryotic organism or a eukaryotic organism to express the Fab'.

[0135] The term "single-chain antibody", "single-chain Fv" or "scFv" means a molecule comprising an antibody heavy chain variable domain (or region; VH) and an antibody light chain variable domain (or region; VL) connected by a linker. Such scFv molecules may have the general structure: NH2-VL-linker-VH-COOH or NH2-VH-linker-VL-COOH. Suitable prior art linkers consist of repeated GGGGS amino acid sequences or variants thereof, for example using variants of 1-4 repeats (Holliger et al. (1993), Proc. Natl. Acad. Sci. USA 90: 6444-6448). Other linkers useful in the present disclosure are described by Alfthan et al. (1995), Protein Eng. 8:725-731, Choi et al. (2001), Eur. J. Immunol. 31:94-106, Hu et al. (1996), Cancer Res. 56:3055-3061, Kipriyanov et al. (1999), J. Mol. Biol. 293:41-56 and Roovers et al. (2001), Cancer Immunol.

[0136] The term "single domain antibody", "single domain antibody" or "sdAb" refers to a new type of antibody that does not contain the CH1 region and light chain of the heavy chain, only contains a single heavy chain variable region, and retains the complete antigen binding activity characteristics, also known as a nanobody. Like a complete antibody, it can selectively bind to a specific antigen. Compared with the mass of 150-160kDa of a complete antibody, a single domain antibody is much smaller, about only 12-15kDa. The first single domain antibody was artificially engineered from the heavy chain antibody of a camel, called the "VHH segment".

[0137] The terms "single domain antibody", "heavy chain variable region domain of a heavy chain antibody", "VHH segment", and "nanobody" are used interchangeably, and a single domain antibody is a variable region of a heavy chain antibody. Typically, a single domain antibody contains three CDRs and four FRs.

[0138] Single domain antibodies can be derived from any species, including mice, humans, camels, llamas, goats, rabbits and cattle. For example, naturally occurring VHH molecules can be derived from antibodies provided by camelid species (e.g., camels, dromedaries, llamas and guanacos). Like complete antibodies, single domain antibodies are able to selectively bind to specific antigens. Single domain antibodies can contain only the variable domains of immunoglobulin chains, which have CDR1, CDR2 and CDR3 and framework regions.

[0139] The term "CDR" refers to one of the six hypervariable regions in the variable domain of an antibody that primarily contribute to antigen binding. One of the most commonly used definitions of the six CDRs is provided by Kabat EA et al. (1991) Sequences of proteins of immunological interest. NIH Publication 91-3242). As used herein, the Kabat definition of CDR applies only to CDR1, CDR2 and CDR3 (CDR L1, CDR L2, CDR L3 or L1, L2, L3) of the light chain variable domain, and CDR2 and CDR3 (CDR H2, CDR H3 or H2, H3) of the heavy chain variable domain.

[0140] The term "antibody framework" refers to a portion of a variable domain VL or VH that serves as a scaffold for the antigen binding loops (CDRs) of the variable domain. Essentially, it is a variable domain without CDRs.

[0141] The term "epitope" or "antigenic determinant" refers to the site on an antigen to which an immunoglobulin or antibody specifically binds. An epitope typically includes at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 consecutive or non-continuous amino acids in a unique spatial conformation. See, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, G.E. Morris, Ed. (1996).

[0142] The terms "specific binding", "selective binding", "selectively binds" and "specifically binds" refer to the binding of an antibody to a predetermined epitope on an antigen. Typically, the antibody binds with an affinity (KD) of about less than 10-7M, such as about less than 10-8M, 10-9M or 10-10M or less.

[0143] The term "nucleic acid molecule" refers to DNA molecules and RNA molecules. Nucleic acid molecules can be single-stranded or double-stranded, but are preferably double-stranded DNA. A nucleic acid is "operably linked" when it is placed in a functional relationship with another nucleic acid sequence. For example, if a promoter or enhancer affects the transcription of a coding sequence, then the promoter or enhancer is operably linked to the coding sequence.

[0144] The term "expression vector" refers to a nucleic acid molecule capable of transporting another nucleic acid connected thereto. In one embodiment, the vector is a "plasmid", which refers to a circular double-stranded DNA loop into which other DNA segments can be connected. In another embodiment, the vector is a viral vector, in which other DNA segments can be connected to the viral genome. The vector disclosed herein can replicate autonomously in the host cell introduced therein (e.g., bacterial vectors and additional mammalian vectors with a bacterial origin of replication) or can be integrated into the genome of the host cell after being introduced into the host cell, thereby replicating with the host genome (e.g., non-additional mammalian vectors).

[0145] Methods for producing and purifying antibodies and antigen-binding fragments are well known in the prior art, such as the Cold Spring Harbor Guide to Antibody Experimental Techniques, Chapters 5-8 and 15. Antigen-binding fragments can also be prepared by conventional methods. The antibodies or antigen-binding fragments of the invention are genetically engineered to add one or more human FR regions to the non-human CDR region. Human FR germline sequences can be obtained from the ImMunoGeneTics (IMGT) website http: / / imgt.cines.fr by comparing the IMGT human antibody variable region germline gene database and MOE software, or from the Journal of Immunoglobulins, 2001 ISBN012441351.

[0146] The term "host cell" refers to a cell into which an expression vector has been introduced. Host cells may include bacteria, microorganisms, plants or animal cells. Easily transformed bacteria include members of the family Enterobacteriaceae, such as strains of Escherichia coli or Salmonella; Bacillaceae, such as Bacillus subtilis; Pneumococcus; Streptococcus and Haemophilus influenzae. Suitable microorganisms include Saccharomyces cerevisiae and Pichia pastoris. Suitable animal host cell lines include CHO (Chinese Hamster Ovary Cell Line) and NS0 cells.

[0147] The engineered antibodies or antigen-binding fragments disclosed herein can be prepared and purified by conventional methods. For example, cDNA sequences encoding heavy and light chains can be cloned and recombined into GS expression vectors. The recombinant immunoglobulin expression vector can stably transfect CHO cells. As a more recommended prior art, mammalian expression systems lead to glycosylation of antibodies, especially at the highly conserved N-terminal site of the Fc region. Positive clones are expanded in serum-free culture medium in a bioreactor to produce antibodies. The culture fluid that secretes antibodies can be purified by conventional techniques. For example, purification is performed using an A or G Sepharose FF column containing an adjusted buffer. Non-specifically bound components are washed away. The bound antibodies are then eluted using a pH gradient method, and the antibody fragments are detected by SDS-PAGE and collected. The antibodies can be filtered and concentrated using conventional methods. Soluble mixtures and polymers can also be removed using conventional methods, such as molecular sieves and ion exchange. The resulting product must be immediately frozen, such as at -70°C, or lyophilized.

[0148] The term "peptide" refers to a compound fragment between amino acids and proteins. It is composed of two or more amino acid molecules connected to each other by peptide bonds. It is a structural and functional fragment of protein. Hormones, enzymes, etc. are essentially peptides.

[0149] The term "sugar" refers to a biological macromolecule composed of three elements: C, H, and O, which can be divided into monosaccharides, disaccharides, and polysaccharides.

[0150] The term "fluorescent probe" refers to a class of fluorescent molecules that have characteristic fluorescence in the ultraviolet-visible-near infrared region, and whose fluorescence properties (excitation and emission wavelengths, intensity, lifetime and polarization, etc.) can change sensitively with the properties of the environment, such as polarity, refractive index, viscosity, etc. They non-covalently interact with nucleic acids (DNA or RNA), proteins or other macromolecular structures to change one or several fluorescence properties, and can be used to study the properties and behaviors of macromolecules.

[0151] The term "toxic drug" refers to a substance that inhibits or prevents the function of cells and / or causes cell death or destruction. It includes toxins and other compounds that can be used for tumor treatment.

[0152] The term "alkyl" refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 12 carbon atoms, more preferably an alkyl group containing 1 to 10 carbon atoms, and most preferably an alkyl group containing 1 to 6 carbon atoms (including 1, 2, 3, 4, 5 or 6 carbon atoms). Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2, 3-Dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched chain isomers thereof. More preferred are lower alkyl groups having 1 to 6 carbon atoms, non-limiting examples of which include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, and the like. The alkyl group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any available point of attachment. The substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, and oxo.

[0153] The term "heteroalkyl" refers to an alkyl group containing one or more heteroatoms selected from N, O or S, wherein alkyl is as defined above.

[0154] The term "alkylene" refers to a saturated straight or branched aliphatic hydrocarbon group having two residues derived from the same carbon atom or two different carbon atoms of a parent alkane by removing two hydrogen atoms, and is a straight or branched group containing 1 to 20 carbon atoms, preferably 1 to 12 carbon atoms, and more preferably 1 to 6 carbon atoms (including 1, 2, 3, 4, 5 or 6 carbon atoms). Non-limiting examples of alkylene groups include, but are not limited to, methylene (-CH2-), 1,1-ethylene (-CH(CH3)-), 1,2-ethylene (-CH2CH2)-, 1,1-propylene (-CH(CH2CH3)-), 1,2-propylene (-CH2CH(CH3)-), 1,3-propylene (-CH2CH2CH2-), 1,4-butylene (-CH2CH2CH2CH2-), and 1,5-butylene (-CH2CH2CH2CH2CH2-), and the like. The alkylene group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any available point of attachment. The substituent is preferably independently selected from one or more substituents selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio and oxo.

[0155] The term "alkoxy" refers to-O-(alkyl) and-O-(non-substituted cycloalkyl), wherein the definition of alkyl or cycloalkyl is as described above. Non-limiting examples of alkoxy include: methoxy, ethoxy, propoxy, butoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy. Alkoxy can be optionally substituted or non-substituted, and when substituted, substituents are preferably one or more of the following groups, which are independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, sulfhydryl, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio.

[0156] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, wherein the cycloalkyl ring contains 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms, more preferably 3 to 10 carbon atoms, and most preferably 3 to 8 carbon atoms (containing 3, 4, 5, 6, 7 or 8 carbon atoms). Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, etc.; polycyclic cycloalkyls include spirocyclic, fused and bridged cycloalkyls.

[0157] The term "heterocyclyl" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent containing 3 to 20 ring atoms, one or more of which is selected from nitrogen, oxygen or S(O). m (wherein m is an integer of 0, 1 or 2) heteroatoms, but excluding the ring portion of -OO-, -OS- or -SS-, the remaining ring atoms are carbon. Preferably, it contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms (1, 2, 3 or 4 heteroatoms); more preferably, the cycloalkyl ring contains 3 to 10 ring atoms (including 3, 4, 5, 6, 7, 8, 9 or 10 ring atoms). Non-limiting examples of monocyclic heterocyclic groups include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, etc. Polycyclic heterocyclic groups include spirocyclic, fused ring and bridged ring heterocyclic groups.

[0158] The term "spiro heterocyclyl" refers to a polycyclic heterocyclic group in which the monocyclic rings of 5 to 20 members share one atom (called a spiro atom), wherein one or more of the ring atoms is selected from nitrogen, oxygen or S(O) m (wherein m is an integer 0 to 2) heteroatom, and the remaining ring atoms are carbon. It may contain one or more double bonds, but no ring has a completely conjugated π electron system. Preferably, it is 6 to 14 yuan, more preferably 7 to 10 yuan. According to the number of shared spiral atoms between rings, the spiral heterocyclic group is divided into a single spiral heterocyclic group, a double spiral heterocyclic group or a multi-spiro heterocyclic group, preferably a single spiral heterocyclic group and a double spiral heterocyclic group. More preferably, it is a 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 5 yuan or 5 yuan / 6 yuan single spiral heterocyclic group. Non-limiting examples of spiral heterocyclic groups include:

[0159]

[0160] The term "fused heterocyclyl" refers to a polycyclic heterocyclic group of 5 to 20 members, each ring in the system shares a pair of adjacent atoms with other rings in the system, one or more rings may contain one or more double bonds, but no ring has a completely conjugated π electron system, wherein one or more ring atoms are selected from nitrogen, oxygen or S(O) m (wherein m is an integer of 0, 1 or 2) heteroatoms, and the remaining ring atoms are carbon. Preferably 6 to 14 members, more preferably 7 to 10 members (7, 8, 9 or 10 rings). According to the number of constituent rings, it can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic condensed heterocyclic group, preferably a bicyclic or tricyclic, more preferably a 5-membered / 5-membered or 5-membered / 6-membered bicyclic condensed heterocyclic group. Non-limiting examples of condensed heterocyclic groups include:

[0161]

[0162] The term "bridged heterocyclyl" refers to a 5- to 14-membered polycyclic heterocyclic group in which any two rings share two atoms that are not directly connected, which may contain one or more double bonds, but none of the rings has a completely conjugated π-electron system, and one or more of the ring atoms is selected from nitrogen, oxygen or S(O) m (wherein m is an integer of 0, 1 or 2) heteroatoms, and the remaining ring atoms are carbon. Preferably 6 to 14 members, more preferably 7 to 10 members (7-membered, 8-membered, 9-membered or 10-membered ring). According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocyclic groups, preferably bicyclic, tricyclic or tetracyclic, more preferably bicyclic or tricyclic. Non-limiting examples of bridged heterocyclic groups include:

[0163]

[0164] The heterocyclyl ring may be fused to an aryl, heteroaryl or cycloalkyl ring, wherein the ring attached to the parent structure is a heterocyclyl, non-limiting examples of which include:

[0165] wait.

[0166] The heterocyclic group may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio, and oxo.

[0167] The term "aryl" refers to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (i.e., rings that share adjacent pairs of carbon atoms) group having a conjugated π electron system, preferably 6- to 10-membered (6-, 7-, 8-, 9-, or 10-membered), such as phenyl and naphthyl, preferably phenyl. The aryl ring may be fused to a heteroaryl, heterocyclyl, or cycloalkyl ring, wherein the ring connected to the parent structure is an aryl ring, non-limiting examples of which include:

[0168]

[0169]

[0170] The aryl group may be substituted or unsubstituted. When substituted, the substituent is preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio.

[0171] The term "heteroaryl" refers to a heteroaromatic system containing 1 to 4 heteroatoms (1, 2, 3 or 4 heteroatoms), 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur and nitrogen. Heteroaryl is preferably 5 to 10 yuan (5 yuan, 6 yuan, 7 yuan, 8 yuan, 9 yuan or 10 yuan heteroaryl), more preferably 5 yuan or 6 yuan, such as furanyl, thienyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidyl, pyrazinyl, imidazolyl, tetrazolyl, etc. The heteroaryl ring can be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring connected to the parent structure is a heteroaryl ring, and its non-limiting examples include:

[0172]

[0173] The heteroaryl group may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkyloxy, heterocycloalkyloxy, cycloalkylthio, heterocycloalkylthio.

[0174] The term "amino protecting group" is to protect the amino group with a group that is easily removed in order to keep the amino group unchanged when other parts of the molecule react. Non-limiting examples include 9-fluorenylmethoxycarbonyl, tert-butyloxycarbonyl, acetyl, benzyl, allyl and p-methoxybenzyl. These groups can be optionally substituted with 1-3 substituents (1, 2 or 3 substituents) selected from halogen, alkoxy or nitro. The amino protecting group is preferably 9-fluorenylmethoxycarbonyl.

[0175] The term "haloalkyl" refers to an alkyl group substituted with one or more halogens, wherein alkyl is as defined above.

[0176] The term "deuterated alkyl" refers to an alkyl group substituted with one or more deuterium atoms, wherein alkyl is as defined above.

[0177] The term "hydroxyalkyl" refers to an alkyl group substituted with one or more hydroxy groups, wherein alkyl is as defined above.

[0178] The term "hydroxy" refers to an -OH group.

[0179] The term "halogen" refers to fluorine, chlorine, bromine or iodine.

[0180] The term "amino" refers to -NH2.

[0181] The term "nitro" refers to -NO2.

[0182] The term "cyano" refers to -CN.

[0183] The term "amido" refers to -C(O)N(alkyl) or (cycloalkyl), wherein alkyl and cycloalkyl are as defined above.

[0184] The term "carboxylate" refers to -C(O)O(alkyl) or (cycloalkyl), wherein alkyl and cycloalkyl are as defined above.

[0185] The present disclosure also includes various deuterated forms of compounds of formula (I). Each available hydrogen atom connected to a carbon atom can be independently replaced by a deuterium atom. Those skilled in the art can synthesize deuterated forms of compounds of formula (I) with reference to relevant literature. Commercially available deuterated starting materials can be used when preparing deuterated forms of compounds of formula (I), or they can be synthesized using deuterated reagents using conventional techniques, and deuterated reagents include but are not limited to deuterated borane, trideuterated borane tetrahydrofuran solution, deuterated lithium aluminum hydride, deuterated ethyl iodide and deuterated methyl iodide, etc.

[0186] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and the description includes instances where the event or circumstance occurs or does not occur. For example, "a heterocyclic group optionally substituted with an alkyl group" means that an alkyl group may but need not be present, and the description includes instances where the heterocyclic group is substituted with an alkyl group and instances where the heterocyclic group is not substituted with an alkyl group.

[0187] "Substituted" means that one or more hydrogen atoms, preferably up to 5, more preferably 1, 2 or 3 hydrogen atoms in a group are replaced independently of each other by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and those skilled in the art can determine (by experiment or theory) possible or impossible substitutions without undue effort. For example, amino or hydroxy groups with free hydrogens may be unstable when combined with carbon atoms with unsaturated (e.g. olefinic) bonds.

[0188] The term "pharmaceutical composition" refers to a mixture containing one or more compounds described herein or their physiologically / pharmaceutically acceptable salts or prodrugs and other chemical components, as well as other components such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitate the absorption of the active ingredient, and thus exert biological activity.

[0189] The term "pharmaceutically acceptable salt" or "pharmaceutically acceptable salt" refers to a salt of the ligand-drug conjugate of the present disclosure, or a salt of a compound described in the present disclosure. Such salts are safe and effective when used in mammals and have the desired biological activity. The ligand-drug conjugate of the present disclosure contains at least one amino group and can therefore form salts with acids. Non-limiting examples of pharmaceutically acceptable salts include hydrochloride, hydrobromide, hydroiodide, sulfate, hydrogensulfate, citrate, acetate, succinate, ascorbate, oxalate, nitrate, sorbate, hydrogenphosphate, dihydrogenphosphate, salicylate, hydrogencitrate, tartrate, maleate, fumarate, formate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, and p-toluenesulfonate.

[0190] The term "solvate" refers to a pharmaceutically acceptable solvate formed by the ligand-drug conjugate of the present disclosure and one or more solvent molecules. Non-limiting examples of solvent molecules include water, ethanol, acetonitrile, isopropanol, DMSO, ethyl acetate.

[0191] The term "drug loading" refers to the average number of cytotoxic drugs loaded on each ligand in the molecule of formula (I), and can also be expressed as the ratio of the amount of drug to the amount of antibody. The range of drug loading can be 0-12, preferably 1-10 cytotoxic drugs (D) connected to each ligand (Pc). In the embodiments of the present disclosure, the drug loading is expressed as n, which can also be called the DAR value, and is exemplified by the average of 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10. The average number of drugs per ADC molecule after the coupling reaction can be identified by conventional methods such as UV / visible light spectroscopy, mass spectrometry, ELISA test and HPLC characteristics.

[0192] In one embodiment of the present disclosure, the cytotoxic drug is coupled to the N-terminal amino group of the ligand and / or the ε-amino group of the lysine residue through a linker. Generally, the number of drug molecules that can be coupled to the antibody in the coupling reaction will be less than the theoretical maximum value.

[0193] The loading of the ligand cytotoxic drug conjugate can be controlled by the following non-limiting methods, including:

[0194] (1) Control the molar ratio of the linking reagent and the monoclonal antibody,

[0195] (2) Control the reaction time and temperature,

[0196] (3) Select different reaction reagents.

[0197] The preparation of conventional pharmaceutical compositions is described in the Chinese Pharmacopoeia.

[0198] The term "carrier" is used for the drugs disclosed herein and refers to a system that can change the way the drug enters the human body and its distribution in the body, control the release rate of the drug, and deliver the drug to the targeted organ. The drug carrier release and targeting system can reduce drug degradation and loss, reduce side effects, and improve bioavailability. For example, polymer surfactants that can be used as carriers can self-assemble to form various forms of aggregates due to their unique amphiphilic structure, and preferred examples are micelles, microemulsions, gels, liquid crystals, vesicles, etc. These aggregates have the ability to encapsulate drug molecules and have good permeability to membranes, and can be used as excellent drug carriers.

[0199] The term "excipient" refers to the additives in pharmaceutical preparations other than the main drug, which can also be called auxiliary materials. For example, the binders, fillers, disintegrants, and lubricants in tablets; the matrix part in semi-solid preparations such as ointments and creams; preservatives, antioxidants, flavoring agents, aromatics, cosolvents, emulsifiers, solubilizers, osmotic pressure regulators, colorants, etc. in liquid preparations can all be called excipients.

[0200] The term "diluent" is also called filler, and its main purpose is to increase the weight and volume of the tablet. The addition of diluent not only ensures a certain volume, but also reduces the dosage deviation of the main ingredients and improves the compression molding of the drug. When the drug in the tablet contains oily components, an absorbent needs to be added to absorb the oily substance and keep it in a "dry" state to facilitate tableting. Such as starch, lactose, inorganic salts of calcium, microcrystalline cellulose, etc.

[0201] The pharmaceutical composition may be in the form of a sterile injectable aqueous solution. Among the acceptable solvents and solvents that may be used are water, Ringer's solution, and isotonic sodium chloride solution. The sterile injectable preparation may be a sterile injectable oil-in-water microemulsion in which the active ingredient is dissolved in an oil phase. For example, the active ingredient is dissolved in a mixture of soybean oil and lecithin. The oil solution is then added to a mixture of water and glycerol and processed to form a microemulsion. The injection or microemulsion may be injected into the patient's bloodstream by local mass injection. Alternatively, it is preferred that the solution and microemulsion be administered in a manner that maintains a constant circulating concentration of the disclosed compound. To maintain such a constant concentration, a continuous intravenous drug delivery device may be used. An example of such a device is the Deltec CADD-PLUS.TM.5400 intravenous injection pump.

[0202] The pharmaceutical composition can be in the form of a sterile injection water or oil suspension for intramuscular and subcutaneous administration. The suspension can be prepared according to known techniques with suitable dispersants or wetting agents and suspending agents as described above. Sterile injection preparations can also be sterile injection solutions or suspensions prepared in non-toxic parenterally acceptable diluents or solvents, such as solutions prepared in 1,3-butanediol. In addition, sterile fixed oils can be conveniently used as solvents or suspension media. For this purpose, any blended fixed oils including synthetic mono- or diglycerides can be used. In addition, fatty acids such as oleic acid can also be used to prepare injections.

[0203] The present disclosure relates to a type of cleavable linker with a specific structure and an active substance with a specific structure, and an antibody-drug conjugate (ADC) composed of the linker, the active substance and the antibody. This type of ADC is a complex formed by connecting a toxic substance to an antibody via a spacer. The antibody-drug conjugate (ADC) is degraded in the body to release active molecules, thereby playing an anti-tumor role. DETAILED DESCRIPTION

[0204] The following examples are used to further describe the present disclosure, but these examples are not intended to limit the scope of the present disclosure. Experimental methods in the examples of the present disclosure that do not specify specific conditions are usually carried out according to conventional conditions, such as the Cold Spring Harbor Antibody Technology Laboratory Manual and the Molecular Cloning Manual; or according to the conditions recommended by the raw material or product manufacturer. Reagents that do not specify specific sources are conventional reagents purchased from the market.

[0205] Example 1. Preparation of human / monkey CD228 extracellular domain and truncated protein

[0206] The nucleic acid sequences of amino acids 20-709 (extracellular domain) of human CD228 protein (GenBank, accession number: NP_005920.2), amino acids 20-365 (TFLD1 domain) of human CD228 protein and amino acids 20-712 (extracellular domain) of monkey CD228 protein (GenBank, accession number: XP_015300315.1) were selected, and polyhistidine (His) tags and human immunoglobulin gamma 1 (human IgG1) Fc tags were added to their N-termini, respectively, and the sequences are shown in SEQ ID NO: 1-8. Recombinant mouse CD228-His tag fusion protein (purchased from Sino Biological, Cat. 50994-M08H) was selected from amino acids 1-708 of mouse CD228 protein (GenBank, accession number: NP_038928.1), and the His tag was fused to the C-terminus of the mouse CD228 protein.

[0207] >Human CD228 full length protein

[0208] MRGPSGALWLLLALRTVLG GMEVRWCATSDPEQHKCGNMSEAFREAGIQPSLL

[0209] CVRGTSADHCVQLIAAQEADAITLDGGAIYEAGKEHGLKPVVGEVYDQEVGTS

[0210] YYAVAVVRRSSHVTIDTLKGVKSCHTGINRTVGWNVPVGYLVESGRLSVMGCD

[0211] VLKAVSDYFGGSCVPGAGETSYSESLCRLCRGDSSGEGVCDKSPLERYYDYSGA

[0212] FRCLAEGAGDVAFVKHSTVLENTDGKTLPSWGQALLSQDFELLCRDGSRADVT

[0213] EWRQCHLARVPAHAVVVRADTDGGLIFRLLNEGQRLFSHEGSSFQMFSSEAYG

[0214] QKDLLFKDSTSELVPIATQTYEAWLGHEYLHAMKGLLCDPNRLPPYLRWCVLS

[0215] TPEIQKCGDMAVAFRRQRLKPEIQCVSAKSPQHCMERIQAEQVDAVTLSGEDIYT

[0216] AGKTYGLVPAAGEHYAPEDSSNSYYVVAVVRRDSSHAFTLDELRGKRSCHAGF

[0217] GSPAGWDVPVGALIQRGFIRPKDCDVLTAVSEFFNASCVPVNNPKNYPSSLCAL

[0218] CVGDEQGRNKCVGNSQERYYGYRGAFRCLVENAGDVAFVRHTTVFDNTNGHN

[0219] SEPWAAELRSEDYELLCPNGARAEVSQFAACNLAQIPPHAVMVRPDTNIFTVYG

[0220] LLDKAQDLFGDDHNKNGFKMFDSSNYHGQDLLFKDATVRAVPVGEKTTYRGW

[0221] LGLDYVAALEGMSSQQC SGAAAPAPGAPLLPLLLPALAARLLPPAL

[0222] (SEQ ID NO:1)

[0223] >Human CD228(20-709)-His tag fusion protein

[0224] HHHHHH GMEVRWCATSDPEQHKCGNMSEAFREAGIQPSLLCVRGTSADHCVQ

[0225] LIAAQEADAITLDGGAIYEAGKEHGLKPVVGEVYDQEVGTSYYAVAVVRRSSH

[0226] VTIDTLKGVKSCHTGINRTVGWNVPVGYLVESGRLSVMGCDVLKAVSDYFGGS

[0227] CVPGAGETSYSESLCRLCRGDSSGEGVCDKSPLERYYDYSGAFRCLAEGAGDV

[0228] AFVKHSTVLENTDGKTLPSWGQALLSQDFELLCRDGSRADVTEWRQCHLARVP

[0229] AHAVVVRADTDGGLIFRLLNEGQRLFSHEGSSFQMFSSEAYGQKDLLFKDSTSE

[0230] LVPIATQTYEAWLGHEYLHAMKGLLCDPNRLPPYLRWCVLSTPEIQKCGDMAV

[0231] AFRRQRLKPEIQCVSAKSPQHCMERIQAEQVDAVTLSGEDIYTAGKTYGLVPAA

[0232] GEHYAPEDSSNSYYVVAVVRRDSSHAFTLDELRGKRSCHAGFGSPAGWDVPVG

[0233] ALIQRGFIRPKDCDVLTAVSEFFNASCVPVNNPKNYPSSLCALCVGDEQGRNKC

[0234] VGNSQERYYGYRGAFRCLVENAGDVAFVRHTTVFDNTNGHNSEPWAAELRSE

[0235] DYELLCPNGARAEVSQFAACNLAQIPPHAVMVRPDTNIFTVYGLLDKAQDLFG

[0236] DDHNKNGFKMFDSSNYHGQDLLFKDATVRAVPVGEKTTYRGWLGLDYVAALE

[0237] GMSSQQC

[0238] (SEQ ID NO:2)

[0239] >Human CD228 (20 - 709)-hIgG1 Fc fusion protein

[0240] EPKSADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED

[0241] PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC

[0242] KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSD

[0243] IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH

[0244] EALHNHYTQKSLSLSPGK GMEVRWCATSDPEQHKCGNMSEAFREAGIQPSLLC

[0245] VRGTSADHCVQLIAAQEADAITLDGGAIYEAGKEHGLKPVVGEVYDQEVGTSY

[0246] YAVAVVRRSSHVTIDTLKGVKSCHTGINRTVGWNVPVGYLVESGRLSVMGCDV

[0247] LKAVSDYFGGSCVPGAGETSYSESLCRLCRGDSSGEGVCDKSPLERYYDYSGAF

[0248] RCLAEGAGDVAFVKHSTVLENTDGKTLPSWGQALLSQDFELLCRDGSRADVTE

[0249] WRQCHLARVPAHAVVVRADTDGGLIFRLLNEGQRLFSHEGSSFQMFSSEAYGQ

[0250] KDLLFKDSTSELVPIATQTYEAWLGHEYLHAMKGLLCDPNRLPPYLRWCVLSTP

[0251] EIQKCGDMAVAFRRQRLKPEIQCVSAKSPQHCMERIQAEQVDAVTLSGEDIYTA

[0252] GKTYGLVPAAGEHYAPEDSSNSYYVVAVVRRDSSHAFTLDELRGKRSCHAGFG

[0253] SPAGWDVPVGALIQRGFIRPKDCDVLTAVSEFFNASCVPVNNPKNYPSSLCALC

[0254] VGDEQGRNKCVGNSQERYYGYRGAFRCLVENAGDVAFVRHTTVFDNTNGHNS

[0255] EPWAAELRSEDYELLCPNGARAEVSQFAACNLAQIPPHAVMVRPDTNIFTVYGL

[0256] LDKAQDLFGDDHNKNGFKMFDSSNYHGQDLLFKDATVRAVPVGEKTTYRGWL

[0257] GLDYVAALEGMSSQQC

[0258] (SEQ ID NO:3)

[0259] (Note: The underlined amino acids are 20-709 of human CD228)

[0260] >Human CD228 TFLD1(20-365)-His tag fusion protein

[0261] HHHHHH GMEVRWCATSDPEQHKCGNMSEAFREAGIQPSLLCVRGTSADHCVQ

[0262] LIAAQEADAITLDGGAIYEAGKEHGLKPVVGEVYDQEVGTSYYAVAVVRRSSH

[0263] VTIDTLKGVKSCHTGINRTVGWNVPVGYLVESGRLSVMGCDVLKAVSDYFGGS

[0264] CVPGAGETSYSESLCRLCRGDSSGEGVCDKSPLERYYDYSGAFRCLAEGAGDV

[0265] AFVKHSTVLENTDGKTLPSWGQALLSQDFELLCRDGSRADVTEWRQCHLARVP

[0266] AHAVVVRADTDGGLIFRLLNEGQRLFSHEGSSFQMFSSEAYGQKDLLFKDSTSE

[0267] LVPIATQTYEAWLGHEYLHAMKGLLCDPNRLPPY

[0268] (SEQ ID NO:4)

[0269] >Human CD228 TFLD1(20-365)-hIgG1 Fc fusion protein

[0270] EPKSADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED

[0271] PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC

[0272] KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSD

[0273] IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH

[0274] EALHNHYTQKSLSLSPGK GMEVRWCATSDPEQHKCGNMSEAFREAGIQPSLLC

[0275] VRGTSADHCVQLIAAQEADAITLDGGAIYEAGKEHGLKPVVGEVYDQEVGTSY

[0276] YAVAVVRRSSHVTIDTLKGVKSCHTGINRTVGWNVPVGYLVESGRLSVMGCDV

[0277] LKAVSDYFGGSCVPGAGETSYSESLCRLCRGDSSGEGVCDKSPLERYYDYSGAF

[0278] RCLAEGAGDVAFVKHSTVLENTDGKTLPSWGQALLSQDFELLCRDGSRADVTE

[0279] WRQCHLARVPAHAVVVRADTDGGLIFRLLNEGQRLFSHEGSSFQMFSSEAYGQ

[0280] KDLLFKDSTSELVPIATQTYEAWLGHEYLHAMKGLLCDPNRLPPY

[0281] (SEQ ID NO:5)

[0282] (Note: The underlined amino acids are 20-365 of human CD228)

[0283] >Monkey CD228 full length protein

[0284] MRGPSRALWLLLALRTVLG GMEVRWCVTSDPEQQKCSNMSTAFREAGIQPSLL

[0285] CVQGTSPDHCIQLIAAQEADAITLDGGAIYEAGKEHGLKPVVGEVYDQEVGTS

[0286] YYAVAVVKRSSQVTINTLKGVKSCHTGINRTVGWNVPVGYLVESGRLSVMGCD

[0287] VLKAVSDYFGGSCVPGAGETRYSESLCRLCRGDSSGEGVCDKSPLERYYDYSG

[0288] AFRCLAEGAGDVAFVKHSTVLENTDGKTLPSWGQALLSQDFELLCRDGSRADV

[0289] TEWRQCHLARVPAHAVVVRADTDGGLIFRLLNEGQRLFSHEGSSFQMFSSKAY

[0290] GQKDLLFKDSTSELVPIATQTYEAWLGQEYLHAMKGLLCDPNRLPPYLRWCVL

[0291] STPEIQKCGDMAVAFGRQQLKPEIQCVSAKSPQHCMEQIQAGQIDTVTLSGEDIY

[0292] TAGKTYGLAPAAGEGYASEDSSNSYFVVAVVRRDSSHAFTLDELRGKRSCHAGF

[0293] GSPAGWDIPVGALIRRGFIRPKDCDVLTAVSEFFNASCVPVNNPKNYPSSLCALC

[0294] VGDEQGRNKCVGNSQERYYGNSGAFRCLVENAGDVAFVRHTTVFDNTNGHNS

[0295] EPWAAELRSEDYELLCPNGARAEVSQFAACNLAQMPPHAVMVRPDTNIFTVYG

[0296] LLDKAQDLFGDDHNKNGFKMFDSSNYHGQDLLFKDATVRAVPVGEKTTYRDW

[0297] LGLDYVAALEGMLSEQCSGA GRAGPPRRLPGAVQTPLPQNLEGAGRGCCGSGE

[0298] AGGGRFTAVRSRRGAGPPPPRSPAPPSARPPGDAVATEAPTSGGCSQALQGGPAP

[0299] APTGPARGTAASAGGGGREAEPGRRGETRRGPLEEGTLSRVGAPVPPTAHALGG

[0300] RPAPGTLCPASSPTVAAPAPARASRPRIPLLSLLRLSPPAPPWMPTARTHARAAPS

[0301] LKGAGGEPPEGLGVGTRHSSGSERGWGVSSGSSLGPAPTGPGTAHAPFPPLREA

[0302] AERAWPGPLSTPFCQLSEKPKKVSRTASP

[0303] (SEQ ID NO:6)

[0304] >Rhesus CD228 (20 - 712)-His tag fusion protein

[0305] HHHHHH GMEVRWCVTSDPEQQKCSNMSTAFREAGIQPSLLCVQGTSPDHCIQLI

[0306] AAQEADAITLDGGAIYEAGKEHGLKPVVGEVYDQEVGTSYYAVAVVKRSSQVT

[0307] INTLKGVKSCHTGINRTVGWNVPVGYLVESGRLSVMGCDVLKAVSDYFGGSCV

[0308] PGAGETRYSESLCRLCRGDSSGEGVCDKSPLERYYDYSGAFRCLAEGAGDVAF

[0309] VKHSTVLENTDGKTLPSWGQALLSQDFELLCRDGSRADVTEWRQCHLARVPA

[0310] HAVVVRADTDGGLIFRLLNEGQRLFSHEGSSFQMFSSKAYGQKDLLFKDSTSEL

[0311] VPIATQTYEAWLGQEYLHAMKGLLCDPNRLPPYLRWCVLSTPEIQKCGDMAVA

[0312] FGRQQLKPEIQCVSAKSPQHCMEQIQAGQIDTVTLSGEDIYTAGKTYGLAPAAG

[0313] EGYASEDSSNSYFVVAVVRRDSSHAFTLDELRGKRSCHAGFGSPAGWDIPVGAL

[0314] IRRGFIRPKDCDVLTAVSEFFNASCVPVNNPKNYPSSLCALCVGDEQGRNKCVG

[0315] NSQERYYGNSGAFRCLVENAGDVAFVRHTTVFDNTNGHNSEPWAAELRSEDYE

[0316] LLCPNGARAEVSQFAACNLAQMPPHAVMVRPDTNIFTVYGLLDKAQDLFGDD

[0317] HNKNGFKMFDSSNYHGQDLLFKDATVRAVPVGEKTTYRDWLGLDYVAALEG

[0318] MLSEQCSGA

[0319] (SEQ ID NO:7)

[0320] >-Simian CD228 (20 - 712)-hIgG1 Fc fusion protein

[0321] EPKSADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED

[0322] PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC

[0323] KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSD

[0324] IAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH

[0325] EALHNHYTQKSLSLSPGK GMEVRWCVTSDPEQQKCSNMSTAFREAGIQPSLLC

[0326] VQGTSPDHCIQLIAAQEADAITLDGGAIYEAGKEHGLKPVVGEVYDQEVGTSYY

[0327] AVAVVKRSSQVTINTLKGVKSCHTGINRTVGWNVPVGYLVESGRLSVMGCDVL

[0328] KAVSDYFGGSCVPGAGETRYSESLCRLCRGDSSGEGVCDKSPLERYYDYSGAFR

[0329] CLAEGAGDVAFVKHSTVLENTDGKTLPSWGQALLSQDFELLCRDGSRADVTE

[0330] WRQCHLARVPAHAVVVRADTDGGLIFRLLNEGQRLFSHEGSSFQMFSSKAYGQ

[0331] KDLLFKDSTSELVPIATQTYEAWLGQEYLHAMKGLLCDPNRLPPYLRWCVLSTP

[0332] EIQKCGDMAVAFGRQQLKPEIQCVSAKSPQHCMEQIQAGQIDTVTLSGEDIYTA

[0333] GKTYGLAPAAGEGYASEDSSNSYFVVAVVRRDSSHAFTLDELRGKRSCHAGFGS

[0334] PAGWDIPVGALIRRGFIRPKDCDVLTAVSEFFNASCVPVNNPKNYPSSLCALCVG

[0335] DEQGRNKCVGNSQERYYGNSGAFRCLVENAGDVAFVRHTTVFDNTNGHNSEP

[0336] WAAELRSEDYELLCPNGARAEVSQFAACNLAQMPPHAVMVRPDTNIFTVYGLL

[0337] DKAQDLFGDDHNKNGFKMFDSSNYHGQDLLFKDATVRAVPVGEKTTYRDWL

[0338] GLDYVAALEGMLSEQCSGA

[0339] (SEQ ID NO:8)

[0340] (Note: The underlined amino acids are 20-712 of monkey CD228)

[0341] According to the method well known in the art, plasmids carrying target protein (SEQ ID NO: 1-8) encoding genes were synthesized respectively, and expression vectors containing target protein encoding genes were obtained by enzyme digestion, ligation, and transformation. After DNA sequencing screening, a large number of plasmids were extracted for clones with correct insertion sequences. The extracted expression vectors were transiently expressed in Expi293 cells (purchased from ADCC) for 7 days, and the expression supernatant was separated and purified after ELISA detection, and stored at -70°C for future use.

[0342] Example 2. Construction of a stable cell line expressing recombinant CD228 protein

[0343] HEK293T cells (purchased from ADCC) were transfected with plasmids encoding recombinant human protein (SEQ ID NO: 1) or cynomolgus monkey protein (SEQ ID NO: 1) and then packaged with lentivirus, which was then infected with lentivirus in HEK293T cells. Cell lines stably expressing recombinant human or cynomolgus monkey CD228 protein were obtained by antibiotic pressure screening.

[0344] Specifically, the nucleotide sequence encoding human or cynomolgus monkey CD228 protein was cloned and connected to a lentiviral expression vector and transfected into HEK293T cells to package the lentivirus, the HEK293T cells were transfected using a lentiviral infection method well known in the industry, and resistance screening and culture were performed using DMEM medium containing Puromycin (purchased from Gibco), subcloned in a 96-well culture plate using a limiting dilution method, and cultured in a cell culture incubator, and two weeks later, the expression of CD228 on the surface of HEK293T cells infected with the lentivirus was detected by FACS, and monoclonal cell lines HEK293T-hCD228 and HEK293T-cyno CD228 with high expression of human or monkey CD228 were selected, cultured on an expanded scale, and stored frozen for storage.

[0345] Example 3. Screening of tumor cell lines expressing human CD228 protein

[0346] The expression level of CD228 on the surface of tumor cell lines was detected by FACS, and the antibody used was CD228 antibody BMK1 (sequence see published patent number: US20200246479A1). The cell lines tested included human melanoma cells A2058 (ATCC, catalog number: CRL-11147), human melanoma cells SK-MEL-28 (ATCC, catalog number: HTB-72), human breast cancer cells MD-MB-231 (ATCC, catalog number: CRM-HTB-26) and human colorectal adenocarcinoma epithelial cells DLD-1 (ATCC, catalog number: CCL-221). Tumor cells were cultured according to the culture protocol provided by ATCC. Gradient diluted antibody molecules and control molecules were mixed with 1x 10 5 Cells were incubated at 4°C for 1 hour, excess antibodies were washed off, anti-human Fc antibodies labeled with mouse Alexa Flour 647 were added, and incubated at 4°C for 30 minutes. After washing off excess antibodies, the cells were resuspended in 200 μL 2% FBS / PBS buffer and the fluorescence signals on the cell surface were read by Thermo Attune NxT flow cytometer. The results showed that A2058 and SK-MEL-28 expressed high abundance CD228, MDA-MB-231 expressed moderate levels of CD228, and DLD-1 did not express CD228.

[0347] >BMK1 heavy chain sequence

[0348] QVQLQESGPGLVKPSETLSLTCTVSGDSITSGYWNWIRQPPGKGLEYIGYISDSGITYYNP

[0349] SLKSRVTISRDTSKNQYSLKLSSVTAADTAVYYCARRTLATYYAMDYWGQGTLVTVSSA

[0350] STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG

[0351] LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGP

[0352] SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY

[0353] NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR

[0354] DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:202)

[0355] >BMK1 light chain sequence

[0356] DFVMTQSPLSLPVTLGQPASISCRASQSLVHSDGNTYLHWYQQRPGQSPRLLIYRVSNRF

[0357] SGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPPTFGQGTKLEIKRTVAAPSV

[0358] FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:203) BMK2 sequence is from patent US20170320960A1

[0359] >BMK2 heavy chain sequence

[0360] QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYRIEWVRQAPGQGLEWMGEILPRGGN

[0361] TNYNEKFKGRVTFTADTSTSTAYMELRSLRSDDTAVYYCARDDGYYGRFAYWGQGTLV

[0362] TVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAV

[0363] LQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE

[0364] LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP

[0365] REEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY

[0366] TLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO: 204)

[0367] >BMK2 light chain sequence

[0368] DIQMTQSPSSSLSASVGDRVTITCRASQDISNYLNWYQQKPGKAPKLLIYYTSRLHSGVPS

[0369] RFSGSGSGTDYTLTISSLQPEDFATYYCQQGNTLPPTFGGGTKVEIKRTVAAPSVFIFPPSD

[0370] EQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO: 205)

[0371] Example 4. Screening of mouse anti-CD228 monoclonal antibodies

[0372] The recombinant human CD228 (20-709)-IgG1 Fc fusion protein or the recombinant human CD228 (20-709)-His tag fusion protein in Example 1 was used as an immunogen, and the recombinant human CD228 (20-709)-His tag fusion protein, human CD228 TFLD1 (20-365)-His tag fusion protein and monkey CD228 (20-712)-His tag fusion protein were used for later screening. The HEK293T stable cell line expressing human CD228 in Example 2 or A2058 and SKMEL-28 were used to determine the antiserum titer and screen for antigen-specific antibodies.

[0373] Specifically, recombinant human CD228 (20-709) -IgG1 Fc fusion protein or recombinant human CD228 (20-709) -His tag fusion protein was used as an immunogen to immunize 6-8 week old Balb / c or SJL / J mice. The initial immunization dose was 50 μg per mouse. Two weeks after the initial immunization, booster immunization was performed with an immunization dose of 25 μg per mouse, and each subsequent booster immunization was performed at an interval of 3 weeks. Serum samples were collected one week after each booster immunization, and the antibody activity in the mouse serum was detected by Protein ELISA and FACS. The Protein ELIS detection process is as follows: the plate was coated with 1 μg / mL recombinant human CD228 (20-709) -His tag fusion protein and monkey CD228 (20-712) -His tag fusion protein, overnight at 4 ° C, blocked with 1% BSA / PBST buffer for 1 hour, and washed 3 times. Mouse serum was diluted 10-fold in blocking buffer starting at 1:100, incubated at 37°C for 1 hour, washed 3 times, and incubated with HRP-labeled anti-mouse IgG Fc secondary antibody for 1 hour. Washed 3 times with PBST, 100 μL TMB substrate was added to each well, and the reaction was terminated with 2M HCl after 15 minutes. The absorbance at 450 nm was read using a microplate reader. The FACS detection process was as follows: 1x10 cells were plated per well. 5 / 100μL cells, centrifuge and discard the supernatant, add gradient dilutions of mouse serum. Incubate at 4℃ for 1 hour. Wash twice with 1% BSA / PBS buffer and discard the supernatant, add Alexa Flour 647 goat anti-mouse secondary antibody (purchased from Jackson immuno research), incubate at 4℃ for 30 minutes in the dark. Wash twice with 1% BSA / PBS buffer, resuspend in 200μL buffer and detect by FACS.

[0374] The last immunization was intraperitoneal injection of 100 μg recombinant human CD228 (20-709) -IgG1 Fc fusion protein or recombinant human CD228 (20-709) -His tag fusion protein. The mice were killed 5 days later and the spleen was removed. The spleen cells were collected by grinding. NH4Cl with a final concentration of 1% (w / w) was added to lyse the mixed red blood cells in the spleen cells to obtain a spleen cell suspension. The cells were resuspended and washed three times by centrifugation at 1000 rpm. Mouse spleen cells were mixed with mouse myeloma cells SP2 / 0 at a ratio of 5:1 in terms of the number of live cells, and cell fusion was performed using a high-efficiency electrofusion method. The fused cells were diluted into a 96-well cell culture plate using DMEM medium containing 20% ​​fetal bovine serum and 1×HAT (w / w), 200 μL per well for a total of 1x 10 5cells and placed them in a 37°C incubator with 5% (v / v) CO2. After 14 days, the hybridoma cell supernatant was screened using cell ELISA (HEK293T stable cell line expressing human CD228 and A2058), and negative screening was performed using human CD228 TFLD1 (20-365)-His tag fusion protein. The positive clones were expanded to 24-well cell plates and continued to be cultured at 37°C, 5% (v / v) CO2 using DMEM medium containing 10% (w / v) HT fetal bovine serum. After 3 days, the culture medium of the 24-well cell plate was centrifuged and the supernatant was collected. The binding activity to the human CD228-expressing cell lines A2058 and SKMEL-28 was determined by FACS. The binding activity to the monkey CD228 (20-712)-His tag fusion protein and the human CD228 TFLD1 (20-365)-His tag fusion protein was detected by protein ELISA. The positive clones were selected for two rounds of monoclonalization, and the monoclonal cell lines with excellent binding activity were screened by the above-mentioned flow cytometry and protein ELISA methods. The hybridoma cells in the logarithmic growth phase were collected, and RNA was extracted by Trizol and reverse transcribed (PrimeScript TM Reverse Transcriptase, Takara, cat#2680A). The cDNA obtained by reverse transcription was amplified by PCR and sequenced using mouse Ig-Primer Set (Novagen, TB326 Rev.B 0503). Table 1 lists the amino acid sequences of the variable regions of the anti-CD228 antibodies obtained in the present disclosure, and Tables 2 and 3 are the amino acid sequences of the light and heavy chain CDR regions of the anti-CD228 antibodies obtained in the present disclosure.

[0375] Table 1. Amino acid sequences of the variable regions of mouse anti-CD228 antibodies

[0376]

[0377]

[0378]

[0379] Table 2. Variable region CDR sequences of mouse anti-CD228 antibodies

[0380]

[0381]

[0382] Table 3. Light chain variable region CDR sequences of murine anti-CD228 antibodies

[0383]

[0384]

[0385] Example 5. Preparation of anti-CD228 chimeric antibodies and evaluation of binding activity

[0386] In the context of human immunoglobulin constant regions, mouse variable regions are expressed in mammalian host cells to provide chimeric antibodies. Specifically, the nucleotide sequence encoding the variable region of the mouse monoclonal antibody is cloned into the pcDNA3.4 vector containing the human heavy and light chain constant region (Human IgG1, kappa) protein sequence and then transfected into CHOK1 cells. After 5 days, the cells were centrifuged to remove the cells and the cell culture fluid was filtered. After the pH was adjusted to 7.0, the harvested cell culture supernatant was loaded onto a protein A column, the bound antibody was eluted with glycine, and the eluate was neutralized with 1M Tris. After testing, an anti-CD228 chimeric antibody with mouse VH / VL was obtained.

[0387] The CD228 binding activity of anti-CD228 chimeric antibodies on cells was tested by detecting the fluorescence signal of the antibody bound to the cell surface, and the binding strength of the antibody was evaluated according to the strength of the fluorescence signal. Specifically, the gradient diluted antibody molecules and control molecules were mixed at 1x 10 5 cells, incubated at 4°C for 1 hour, washed off excess antibodies, added mouse Alexa Flour 647-labeled anti-human Fc antibody, incubated at 4°C for 30 minutes, washed off excess antibodies and resuspended in 200 μL 1% BSA / PBS buffer, and read the fluorescence signal on the cell surface by a Thermo Attune NxT flow cytometer. The cells used were the HEK239-CynoCD228 and SK-MEL-28 cell lines expressing monkey CD228 prepared in Example 2.

[0388] At the same time, protein ELISA was used to detect the binding of anti-CD228 chimeric antibodies to human CD228 TFLD1. The specific method is as follows: the plate was coated with 1 μg / mL recombinant human CD228 TFLD1, overnight at 4°C, blocked with 1% BSA / PBST buffer for 1 hour, and washed 3 times. The antibody was diluted 3 times in the blocking buffer starting at 1:100, incubated at 37°C for 1 hour, washed 3 times, and incubated with HRP-labeled anti-human IgG Fc secondary antibody for 1 hour. Wash PBST 5 times, add 100 μL TMB substrate to each well, terminate the reaction with 2M HCl after 5 minutes, and read the absorbance at 450nm using an enzyme reader.

[0389] Example 6. Determination of in vitro cell internalization activity of anti-CD228 chimeric antibodies

[0390] αHFc-CL-MMAF is an anti-human Fc antibody-conjugated toxin MMAF with a cleavable linker. The antibody portion is a polyclonal antibody that can specifically bind to the Fc portion of human IgG. MMAF is a toxic small molecule that inhibits cell division by blocking the polymerization of tubulin. The linker is stable in the extracellular matrix and can be cleaved by lysosomal tissue proteases after entering the cell through endocytosis, thereby releasing the toxin. The endocytic activity of the antibody is thus evaluated based on the cell-killing activity.

[0391] Evaluation of αHFc-CL-MMAF-dependent internalization and immunotoxin activity: αHFc-CL-MMAF and anti-CD228 antibody (αHFc-CL-MMAF and antibody equimolar concentration) were mixed at a volume ratio of 1:1, incubated at 37°C for 30 min, then diluted 3-fold with complete medium, added to A2058 or SK-MEL-28 cells (500 cells / well) plated one day in advance, and incubated at 37°C in a 5% carbon dioxide incubator for 6 days. CellTiter-Glo (purchased from Promega) was added, incubated at room temperature in the dark for 10 min, and chemiluminescence was read on a PerkinElmer.

[0392] Example 7. Anti-CD228 chimeric antibody pH-dependent cell binding assay

[0393] The binding activity of anti-CD228 chimeric antibody on cells at pH 4.5 was tested by detecting the fluorescence signal of the antibody bound to the cell surface, and the binding strength of the antibody was evaluated according to the strength of the fluorescence signal. Specifically, the antibody molecules and control molecules diluted in pH 4.5 PBS gradient were mixed with 1x 10 5 cells, incubated at 4°C for 1 hour, washed off excess antibodies with pH7.2 PBS, added mouse Alexa Flour 647-labeled anti-human Fc antibody, incubated at 4°C for 30 minutes, washed off excess antibodies and resuspended in 200 μL 2% FBS / pH7.2 PBS buffer, and read the fluorescence signal on the cell surface using a Thermo Attune NxT flow cytometer. The cells used were SK-MEL-28 or A2058.

[0394] The binding properties of anti-CD228 chimeric antibodies are summarized in Table 4. The results showed that the cell binding activity and cell killing activity of the 14 candidate antibodies were better than or equivalent to BMK1, among which PR0003 and PR0006 had pH dependent binding activity.

[0395] Table 4. In vitro characterization of anti-CD228 chimeric antibodies

[0396]

[0397] Example 8. Humanization of murine anti-CD228 antibody, removal of PTM and TCE site modification

[0398] After predicting the structure of the mouse monoclonal antibody by homology modeling, the CDR of the mouse antibody was chimerized into a suitable human GermLine framework (Bioinformation. 2014; 10(4): 180-186; Methods Mol Biol. 2019; 1904: 213-230), and then back mutations were introduced at sites that may affect antibody-antigen binding. Finally, the nucleotide sequence encoding the variable region of the humanized monoclonal antibody was cloned into a pcDNA3.4 vector containing human heavy and light chain constant region (Human IgG1, kappa) protein sequences and transfected into CHOK1 cells to prepare antibodies. The variable region frameworks selected for the VH / VL of the mouse antibody during the humanization process are shown in Table 5.

[0399] Table 5. Selection of humanized antibody variable region framework

[0400]

[0401] The obtained humanized VH and VL sequences are shown in Table 6-13.

[0402] Table 6. Amino acid sequences of heavy chain variable region (VH) and light chain variable region (VL) of PR0006 after humanization

[0403]

[0404]

[0405] Table 7. PR0006 humanized antibody variable region sequence

[0406]

[0407]

[0408] Table 8. Amino acid sequences of heavy chain variable region (VH) and light chain variable region (VL) of PR0024 after humanization

[0409]

[0410]

[0411] Table 9. PR0024 humanized antibody variable region sequences

[0412]

[0413] Table 10. Amino acid sequences of heavy chain variable region (VH) and light chain variable region (VL) of PR0010 after humanization

[0414]

[0415]

[0416] Table 11. PR0010 humanized antibody variable region sequences

[0417]

[0418]

[0419] Table 12. Amino acid sequences of heavy chain variable region (VH) and light chain variable region (VL) of PR0003 after humanization

[0420]

[0421] Table 13. PR0003 humanized antibody variable region sequences

[0422]

[0423]

[0424] Based on the humanized antibody transformation, PTM prediction was performed on the antibody, and PTM removal was performed according to the prediction results. The sequence after PTM removal is shown in Table 14.

[0425] Table 14. PR0006 and PR0024 humanized antibody PTM removal of heavy chain variable region (VH)

[0426]

[0427] For humanized antibodies, in order to reduce the immunogenicity of the antibody, possible TCE sites were predicted by software, and after predicting the structure of the humanized antibody by homology modeling, mutations were introduced at sites that may not affect antibody-antigen binding to reduce the predicted number of TCE sites, and antibody molecules with TCE removed were produced according to the aforementioned method. After TCE removal, the sequences shown in Table 15 were obtained.

[0428] Table 15. PR0010 humanized antibody heavy chain variable region (VH) and light chain variable region (VL) sequences after TCE removal

[0429]

[0430] The antibodies in Table 16 were obtained after PTM and TCE removal, wherein PR0102 and PR0104 were the PTM-removed antibodies of PR0100 and PR0088, respectively; HuPR0010_H3_N54S_T71E / L4, HuPR0010_H3 N54S K74E / L4, HuPR0010_H3_N54S_T76S / L4, HuPR0010_H3_N54S / L4 K45D, HuPR0010_H3_N54S T71E / L4K45D, HuPR0010_H3_N54S_K74E / L4 K45D and HuPR0010_H3_N54S_T76S / L4 K45D were obtained by removing TCE from HuPR0010_H3_N54S / L4.

[0431] Table 16. Anti-CD228 antibody variable region sequences modified by PTM and TCE removal

[0432]

[0433]

[0434] The modified VH and VL were used to construct a full-length antibody, and the human IgG1 constant region sequence used was shown in Table 17.

[0435] Table 17. Human IgG1 constant region sequences

[0436]

[0437] Example 9. Antibody signal peptide optimization

[0438] Different signal peptides affect the cleavage of the amino acids at the N-terminus of the PR0102 light chain. Different signal peptides and PR0102 light chain sequences were constructed into pcDNA3.4 vectors and transfected into CHOK1 cells. After the antibodies were expressed and purified, mass spectrometry was performed to detect the complete and heavy and light chain desugar molecular weights to confirm the integrity and ratio of the sequences. The signal peptide and mass spectrometry detection results are shown in Table 18.

[0439] Table 18. Different signal peptides and mass spectrometry detection results

[0440]

[0441] Example 10. Potential effects of deglycosylation on antibody binding

[0442] Mass spectrometry revealed that PR0108 was glycosylated to varying degrees. PTM analysis revealed that there was a glycosylation site in the CDR1 region (LC: K24) of the light chain of PR0108, and the ratio increased during incubation in a sucrose solution. Therefore, the site was mutated and modified, and the sequence is shown in Table 19. After the antibody was expressed and purified, it was incubated in 529 buffer (10 mM acetic acid, 9% sucrose, pH 5.2) at 40°C for two weeks, and the glycosylation ratio was detected by mass spectrometry. The results are shown in Table 21. After the antibody was modified, the glycosylation ratio was significantly improved.

[0443] Table 19. Amino acid sequence of PR0108 light chain variable region (VL) with reduced glycosylation risk

[0444]

[0445] Table 20. Variable region sequences of anti-CD228 antibodies modified by PR0108 to remove the risk of glycosylation

[0446]

[0447] Table 21. Analysis of saccharification ratio after PR0108 was modified to remove saccharification risk

[0448]

[0449]

[0450] Example 11. Antibody modification to increase antibody expression and optimize expression purity

[0451] Homology modeling of HuPR003 H4 / L2 was performed using structural modeling software to analyze the amino acids that potentially affect the expression and aggregation of HuPR003H4 / L2, and rationally designed mutations were performed on these sites to obtain the mutated sequences shown in Table 22. The modified sequences were constructed into pcDNA3.4 vectors and transfected into CHOK1 cells. After expression and purification, the antibodies were subjected to SEC purity testing, in vitro cell binding activity testing, and in vitro endocytosis activity testing.

[0452] Table 22. Amino acid sequences of heavy chain variable region (VH) and light chain variable region (VL) of HuPR003 H4 / L2 after modification

[0453]

[0454]

[0455]

[0456]

[0457] Table 23. HuPR003 H4 / L2 modified antibody variable region sequence

[0458]

[0459]

[0460]

[0461] As shown in Table 24, after the modification, the expression level and SEC purity of the antibody were significantly improved.

[0462] Table 24. Expression and purity information of HuPR003 antibody before and after modification

[0463]

[0464]

[0465] Example 12. Surface Plasmon Resonance (SPR) Assessment of Kinetics of Antibody-CD228 Interaction

[0466] SPR detection was performed using the BIAcore 8K (Cityva) system. The sensor chip protein A and related reagents used for detection were purchased from Cytiva. Under the conditions of HBS-EP+ (pH7.4) and PBS-P (pH6.0), the antibodies PR0108 and HuPR003M25 were diluted to 1μg / mL with HBS-EP+ or PBS-P buffer, respectively, and the flow rate was set to 10μL / min, and the antibody was captured to the level of 200RU. The CD228 antigen with His tag was diluted with HBS-EP+ buffer in a certain proportion to a concentration gradient of 0nM, 3.125nM, 6.25nM, 12.5nM (two replicates), 25nM, 50nM, 100nM, and 200nM. The flow rate was set to 30μL / min during sample analysis. The binding time was 120s and the dissociation time was 900s. Then regeneration was performed, using pH 1.5 Gly-HCl buffer as the regeneration buffer, the regeneration flow rate was set to 30 μL / min, and the regeneration was 30 s. The response signal was based on the analysis time as the horizontal axis and the response value as the vertical axis. The obtained data were fitted by BIAcore 8K analysis software, and the 1:1 Langmuir binding model was used to determine its binding rate constant (K a ), dissociation rate constant (K d ) and dissociation equilibrium constant (K D ) and other kinetic constants.

[0467] The results in Tables 25 and 26 show that PR0108 and HuPR003M25 molecules can bind to human and cynomolgus monkey antigens, and the binding of HuPR003M25 molecule to CD228 has pH-dependent properties.

[0468] Table 25. Binding kinetic parameters of anti-CD228 antibodies to human CD228 at different pH conditions

[0469]

[0470]

[0471] Table 26. Binding kinetic parameters of anti-CD228 antibodies to monkey CD228 (pH 7.4)

[0472]

[0473] Example 13. Epitope grouping between anti-CD228 antibodies

[0474] Epitope grouping experiments were performed using the BIAcore 8K (Cityva) system. The sensor chip anti-Histag and related reagents used for detection were purchased from Cytiva. Under HBS-EP+ (pH 7.4) conditions, the antigen CD228 ECD his tag was diluted to 1 μg / mL with HBS-EP+ buffer, the flow rate was set to 10 μL / min, and the antigen was captured to a level of 200 RU. Antibody 1 was diluted to the required concentration using HBS-EP+ buffer, and injected to bind to the saturation platform to obtain RU(Ab1). Antibody 2 was diluted to the required concentration using HBS-EP+ buffer containing antibody 1, and injected to bind to saturation to obtain RU(Ab1+2). Calculate ΔRU% = (RU(Ab1+2)–RU(Ab1)) / RU(RU when Ab2 is Ab1)×100%. When ΔRU%<10%, the two antibodies have the same epitope; when 20<ΔRU%<80, the epitopes of the two antibodies partially overlap; when ΔRU%>90%, the epitopes of the two antibodies are different. ΔRU% is shown in Table 27. According to the SPR results, HuPR003M25 and BMK2 belong to different epitopes, and HuPR003M25 covers the BMK1 epitope. PR0108M3 partially overlaps with huPR003M25, BMK1, and BMK2 epitopes.

[0475] Table 27. Anti-CD228 Antibody Epitope Grouping ΔRU%

[0476]

[0477] Example 14. Determination of in vitro cell internalization activity of anti-CD228 antibodies

[0478] To verify the internalization of the antibody, αHFc-NC-MMAF toxin was used to assess the endocytic activity of the anti-CD228 antibody.

[0479] αHFc-NC-MMAF is an anti-human Fc antibody-conjugated toxin MMAF with a non-cleavable linker. The antibody portion is a polyclonal antibody that can specifically bind to the Fc portion of human IgG. MMAF is a toxic small molecule that inhibits cell division by blocking the polymerization of tubulin. The linker is stable in the extracellular matrix and can be cleaved by lysosomal tissue proteases after entering the cell through endocytosis, thereby releasing the toxin. The endocytic activity of the antibody is thus evaluated based on the cell-killing activity.

[0480] Evaluation of αHFc-NC-MMAF-dependent internalization and immunotoxin activity: αHFc-NC-MMAF and anti-CD228 antibody (αHFc-NC-MMAF and antibody are in equal molar concentrations) were mixed at a volume ratio of 1:1, incubated at 37°C for 30 minutes, and then diluted 3-fold with complete medium, and A2058 or MDA-MB-231 cells (500 cells / well) plated one day in advance were added, and incubated at 37°C in a 5% carbon dioxide incubator for 6 days. CellTiter-Glo (purchased from Promega) was added, incubated at room temperature in the dark for 10 minutes, and chemiluminescence was read on a PerkinElmer.

[0481] The results showed that, as shown in Figure 1 and Table 29, on A2058 and SK-MEL-28 cells, PR0108 and PR0108M3 were more active than BMK1, while HuPR003M25 was comparable to BMK1 and BMK2. On MDA-MB-231 cells, PR0108, PR0108M3 and HuPR003M25 were more active than BMK1 and BMK2. DLD-1 cells do not express CD228, and all antibodies were inactive.

[0482] Example 15. Cell surface antigen affinity detection of anti-CD228 antibodies

[0483] FACS detection of anti-CD228 antibodies was performed on A2058 cells, SK-MEL-28 cells, MDA-MB-231 cells, DLD-1 cells and HEK293T-cynoCD228 cells by the method described in Example 5. The control antibodies were BMK1 and BMK2. Table 28 and Table 29 summarize the relevant properties of humanized molecules PR0108 and HuPR003M25 antibodies after PTM modification and TCE removal.

[0484] Table 28. Anti-CD228 antibody cell surface antigen affinity detection

[0485]

[0486] Table 29. Endocytic activity of anti-CD228 antibodies

[0487]

[0488]

[0489] *Indicates that the maximum killing plateau has not been reached

[0490] Example 16. Preparation of Antibody Drug Conjugate (ADC)

[0491] In this example, an ADC of an antibody with the following structure coupled with 9106 was prepared, wherein Ab is PR0108, PR0108M3 or HuPR003M25, and the sequence information is shown in Table 30.

[0492]

[0493] Table 30. Antibody Ab heavy chain light chain sequence

[0494]

[0495]

[0496] 1. PR0108-9106-DAR4

[0497] At 37°C, the prepared aqueous solution of tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl) (1.5 mM, 134 μL, 0.20 mmol) was added to the PBS buffer solution of antibody PR0108 (0.05 M PBS buffer solution at pH = 6.5; 5.08 mg / mL, 1.968 mL, 69.4 nmol), placed in a water bath shaker, and shaken at 37°C for 3 hours to stop the reaction. The reaction solution was cooled to 25°C in a water bath.

[0498] Compound 9106 (0.746 mg, 694 nmol) prepared according to WO2020063676A1 was dissolved in 50 μL of dimethyl sulfoxide, added to the above reaction solution, placed in a water bath oscillator, and oscillated at 25°C for 3 hours to stop the reaction. The reaction solution was desalted with a desalting column (buffer: PBS pH 7.2-7.4, flow rate 10 mL / min) to obtain PBS buffer (4.98 mg / mL, 1.92 mL) of PR0108-9106, which was stored in a refrigerator at 4°C.

[0499] The drug loading was calculated by RP-HPLC, and the DAR value was: n=3.9.

[0500] 2. PR0108M3-9106-DAR4

[0501] At 37°C, add the prepared aqueous solution of tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl) (1.5 mM, 134 μL, 0.20 mmol) to the PBS buffer solution of antibody PR0108M3 (pH=6.5 0.05 M PBS buffer solution; 10.0 mg / mL, 1 mL, 69.3 nmol), place in a water bath shaker, shake at 37°C for 3 hours, and stop the reaction. Cool the reaction solution to 25°C in a water bath.

[0502] Compound 9106 (0.744 mg, 693 nmol) prepared according to WO2020063676A1 was dissolved in 50 μL of dimethyl sulfoxide, added to the above reaction solution, placed in a water bath oscillator, and oscillated at 25°C for 3 hours to stop the reaction. The reaction solution was desalted with a desalting column (buffer: PBS pH 7.2-7.4, flow rate 10 mL / min) to obtain PBS buffer (7.13 mg / mL, 1.29 mL) of PR0108M3-9106, which was stored in a refrigerator at 4°C.

[0503] The drug loading was calculated by RP-HPLC, and the DAR value was: n=3.9.

[0504] 3. PR0108M3-9106-DAR8

[0505] At 37°C, add the prepared tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl) aqueous solution (1.5 mM, 553 μL, 0.83 mmol) to the PBS buffer solution of antibody PR0108M3 (pH=6.5 0.05 M PBS buffer solution; 10.0 mg / mL, 1 mL, 69.3 nmol), place in a water bath shaker, shake at 37°C for 3 hours, and stop the reaction. Cool the reaction solution to 25°C in a water bath.

[0506] Compound 9106 (1.49 mg, 1.386 mmol) prepared according to WO2020063676A1 was dissolved in 50 μL of dimethyl sulfoxide, added to the above reaction solution, placed in a water bath oscillator, and oscillated at 25°C for 3 hours to stop the reaction. The reaction solution was desalted with a desalting column (buffer: PBS pH 7.2-7.4, flow rate 10 mL / min) to obtain PBS buffer (6.48 mg / mL, 1.52 mL) of PR0108M3-9106, which was stored in a refrigerator at 4°C.

[0507] The drug loading was calculated by RP-HPLC, and the DAR value was: n=7.1.

[0508] 4. HuPR003M25-9106-DAR4

[0509] At 37°C, add the prepared tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl) aqueous solution (1.5 mM, 111 μL, 0.166 mmol) to the PBS buffer aqueous solution of antibody HuPR003M25 (pH=6.5 0.05 M PBS buffer aqueous solution; 5.07 mg / mL, 1.972 mL, 69.3 nmol), place in a water bath shaker, shake at 37°C for 3 hours, and stop the reaction. Cool the reaction solution to 25°C in a water bath.

[0510] Compound 9106 (0.745 mg, 693 nmol) prepared according to WO2020063676A1 was dissolved in 50 μL of dimethyl sulfoxide, added to the above reaction solution, placed in a water bath oscillator, and oscillated at 25°C for 3 hours to stop the reaction. The reaction solution was desalted with a desalting column (buffer: PBS pH 7.2-7.4, flow rate 10 mL / min) to obtain HuPR003M25-9106 PBS buffer (5.13 mg / mL, 1.79 mL), which was stored in a refrigerator at 4°C.

[0511] The drug loading was calculated by RP-HPLC, and the DAR value was: n=4.1.

[0512] 5. HuPR003M25-9106-DAR8

[0513] At 37°C, add the prepared tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl) aqueous solution (10 mM, 83.2 μL, 0.83 mmol) to the PBS buffer aqueous solution of antibody HuPR003M25 (pH=6.5 0.05 M PBS buffer aqueous solution; 5.07 mg / mL, 1.972 mL, 69.3 nmol), place in a water bath shaker, shake at 37°C for 3 hours, and stop the reaction. Cool the reaction solution to 25°C in a water bath.

[0514] Compound 9106 (1.49 mg, 1.386 mmol) prepared according to WO2020063676A1 was dissolved in 50 μL of dimethyl sulfoxide, added to the above reaction solution, placed in a water bath oscillator, and oscillated at 25°C for 3 hours to stop the reaction. The reaction solution was desalted with a desalting column (buffer: PBS pH 7.2-7.4, flow rate 10 mL / min) to obtain HuPR003M25-9106 PBS buffer (6.17 mg / mL, 1.57 mL), which was stored in a refrigerator at 4°C.

[0515] The drug loading was calculated by RP-HPLC, and the DAR value was: n=7.3.

[0516] 6. BMK1-9106-DAR4

[0517] At 37°C, add the prepared tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl) aqueous solution (1.5 mM, 123 μL, 0.18 mmol) to the PBS buffer aqueous solution of antibody BMK1 (pH=6.5 0.05 M PBS buffer aqueous solution; 8.16 mg / mL, 1.225 mL, 68.4 nmol), place in a water bath shaker, shake at 37°C for 3 hours, and stop the reaction. Cool the reaction solution to 25°C in a water bath.

[0518] Compound 9106 (0.735 mg, 684 nmol) prepared according to WO2020063676A1 was dissolved in 50 μL of dimethyl sulfoxide, added to the above reaction solution, placed in a water bath oscillator, and oscillated at 25 ° C for 3 hours to stop the reaction. The reaction solution was desalted with a desalting column (buffer: PBS pH7.2-7.4, flow rate 10 mL / min) to obtain BMK1-9106 PBS buffer (8.36 mg / mL, 1.16 mL), which was stored in a refrigerator at 4 ° C.

[0519] The drug loading was calculated by RP-HPLC, and the DAR value was: n=3.9.

[0520] 7. BMK1-MMAE-DAR 8

[0521] At 37°C, add the prepared tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl) aqueous solution (1.5 mM, 456 μL, 684 nmol) to the PBS buffer solution of antibody BMK1 (pH=6.5 0.05 M PBS buffer solution; 8.16 mg / mL, 1.225 mL, 68.4 nmol), place in a water bath shaker, shake at 37°C for 3 hours, and stop the reaction. Cool the reaction solution to 25°C in a water bath.

[0522] The compound VcMMAE (1.35 mg, 1.026 mmol; CAS No. 646502-53-6; Bidex Pharmaceuticals) was dissolved in 50 μL of dimethyl sulfoxide, added to the above reaction solution, placed in a water bath oscillator, and oscillated for reaction at 25°C for 3 hours to stop the reaction. The reaction solution was desalted using a desalting column (buffer: PBS pH 7.2-7.4, flow rate 10 mL / min) to obtain BMK1-MMAE PBS buffer (5.66 mg / mL, 1.38 mL), which was stored in a refrigerator at 4°C.

[0523] The drug loading was calculated by RP-HPLC, and the DAR value was: n=7.8.

[0524] Example 17. Evaluation of in vivo antitumor activity of ADC in a subcutaneous transplanted tumor model of CD228-high expressing cells in mice

[0525] The antitumor activity of A2058 and MDA-MB-231 was evaluated in mouse subcutaneous xenograft models.

[0526] A2058 subcutaneous xenograft tumor model: A2058 cells were cultured and 1.0 x 10 7 / 0.1mL (PBS) A2058 cells were inoculated on the right side of the back of Balb / c nude mice (purchased from Beijing Weitong Lihua). The average tumor volume reached ~100-150mm 3 The mice were grouped according to tumor volume and body weight. The drugs were administered by intraperitoneal injection starting from the day of grouping (D0), once a week for a total of 3 times. The tumor volume and body weight were measured twice a week and the data were recorded.

[0527] MDA-MB-231 subcutaneous xenograft tumor model: MDA-MB-231 cells were cultured and 1×10 7 +Matrigel / 0.2ml MDA-MB-231 cells were inoculated subcutaneously on the right back of Balb / c nude mice (purchased from Beijing Weitong Lihua), and the average tumor volume reached ~100-150mm 3 The mice were grouped according to tumor volume and body weight. The drugs were administered by intraperitoneal injection starting from the day of grouping (D0), once a week for a total of 3 times. The tumor volume and body weight were measured twice a week and the data were recorded.

[0528] Tumor volume V = 1 / 2 × a × b 2 , where a and b represent length and width, respectively. Relative tumor volume RTV = Vt / V0, Vt is the tumor volume at the end of the experiment, and V0 is the tumor volume at the time of grouping. TGI represents the maximum tumor growth inhibition during the experiment. TGI = [1-RTV (experimental group) / RTV (control group)] × 100%. As mentioned above, PBS was used as a negative control.

[0529] The experimental data were expressed as mean ± standard error (SEM), and GraphPad Prism 9 software was used for plotting and statistical analysis. The significant differences in tumor volume were compared. The one-way analysis of variance method was used, and multiple comparisons were performed if F was significant. On the last day of the experiment, the tumor volume was compared. PR0108-9106-DAR4 and HuPR003M25-9106-DAR4 had good anti-tumor activity, and at high concentrations, the anti-tumor activity was significantly better than that of BMK antibody.

[0530] The results of the A2058 subcutaneous xenograft tumor model are shown in Tables 31 and 32. Figure 2A , 2B In vivo results showed that PR0108-9106-DAR4 and HuPR003M25-9106-DAR4 could effectively inhibit tumor growth at 10 mpk, while BMK1-9106-DAR4 had no tumor suppressor activity at the same dose. Figure 2B As shown, the experimental animals were in good condition of activity and eating during the administration period, indicating that the test drug had no obvious toxic side effects on the experimental animals, and the animals had good tolerance and safety to the toxin.

[0531] Table 31. Tumor volume of A2058 subcutaneous xenograft tumor model under the action of ADC

[0532]

[0533] Table 32. Antitumor activity of ADC in A2058 subcutaneous xenograft tumor model

[0534] ADC Dose / Route / Regimen TGI(%) Vechile (PBS) ip / QW*3 - PR0108-9106-DAR4 3mg / kg / ip / QW*3 -8 PR0108-9106-DAR4 10 mg / kg / ip / QW*3 59 HuPR003M25-9106-DAR4 3mg / kg / ip / QW*3 3 HuPR003M25-9106-DAR4 10 mg / kg / ip / QW*3 59 BMK1-9106-DAR4 10 mg / kg / ip / QW*3 -8 BMK1-MMAE-DAR8 3mg / kg / ip / QW*3 -8

[0535] The results of the MDA-MB-231 subcutaneous xenograft tumor model are shown in Tables 33 and 34. Figure 3A , 3B In vivo results showed that PR0108-9106-DAR4 and HuPR003M25-9106-DAR4 inhibited tumor growth in a dose-dependent manner and were more potent than BMK1-9106-DAR4 at the same dose; at the same low dose, PR0108-9106-DAR4 and HuPR003M25-9106-DAR4 had stronger tumor inhibitory activity than BMK1-MMAE-DAR8. Figure 3B As shown, the experimental animals were in good condition of activity and eating during the administration period, indicating that the test drug had no obvious toxic side effects on the experimental animals, and the animals had good tolerance and safety to the toxin.

[0536] Table 33. Tumor volume of MDA-MB-231 subcutaneous xenograft tumor model under the action of ADC

[0537]

[0538] Table 34. Antitumor activity of ADC in MDA-MB-231 subcutaneous xenograft tumor model

[0539]

[0540] Example 18. Determination of plasma concentration of ADC

[0541] Nine nude mice (common grade, animal source: Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.) were divided into three groups and injected with PR0108-9106-DAR4, HuPR003M25-9106-DAR4, and BMK1-9106-DAR4 through the tail vein. The single dose was set at 10 mg / kg, and the administration volume was 10 mL / kg (diluted with 0.9% sodium chloride injection).

[0542] For the above experimental mice, blood was collected at the following time points: 4h, 24h, 72h, 7d, 14d, and 17d after the first administration. The blood drug concentration was detected by ELISA. Anti-hFc coated plates were incubated overnight at 4°C. After washing once with 300μL PBST buffer, the diluted test serum was added and incubated at room temperature for 1 hour. Each tube of serum was tested on two plates. After one serum plate was washed three times with 300μL PBST buffer, 100μL HRP-labeled goat anti-human IgG Fc solution was added to each well and incubated at room temperature for one hour. After washing five times with PBST buffer, color development solution was added, and stop solution was added after color development was completed. The OD450 was read by an enzyme reader. Mouse-derived anti-9106 antibody was added to the other plate at a concentration of 1μg / mL, 100μL per well. Incubate at room temperature for 1 hour. After washing three times with PBST buffer, HRP-labeled anti-mouse IgG Fc antibody was added and incubated at room temperature for 1 hour. After washing five times with PBST buffer, the colorimetric solution and stop solution were added. OD450 was read by microplate reader. PK parameters were calculated using non-compartmental model of Phoenix software.

[0543] The results are shown in Table 35, which show that PR0108-9106-DAR4, HuPR003M25-9106-DAR4, and BMK1-9106-DAR4 have similar pharmacokinetic characteristics to monoclonal antibodies, and the linker has good plasma stability.

[0544] Table 35. Pharmacokinetic parameters of ADC drugs in mice

[0545]

[0546] Example 19. Binding ability test of CD228 ADC molecules with different DAR values ​​9106 on different cells

[0547] FACS was used to detect anti-CD228 ADC molecules with different DAR values ​​on human melanoma cells A2058 (ATCC, Catalog No.: CRL-11147) and human breast cancer cells MD-MB-231 (ATCC, Catalog No.: CRM-HTB-26). The control antibody was BMK1. Tumor cells were cultured according to the culture protocol provided by ATCC. Serially diluted antibody molecules and control molecules were mixed with 1x 10 5 cells, incubated at 4°C for 1 hour, washed off the excess antibody, added mouse Alexa Flour 647 labeled anti-human Fc antibody, incubated at 4°C for 30 minutes, washed off the excess antibody and resuspended in 200 μL 2% FBS / PBS buffer, and read the fluorescence signal on the cell surface by Thermo Attune NxT flow cytometer. Table 36 summarizes the relevant binding properties of PR0108 (M3) and HuPR003M25 antibodies conjugated to molecules with different DAR values ​​9106.

[0548] Table 36. Binding assay of molecules with different DAR values ​​on tumor cells

[0549]

[0550] Example 20. Detection of the killing ability of PR0108M3-9106DAR8 and HuPR003M25-9106DAR8 on tumor cells expressing different antigens

[0551] Human melanoma cells A2058 (ATCC, Catalog No.: CRL-11147), human breast cancer cells MD-MB-231 (ATCC, Catalog No.: CRM-HTB-26), human melanoma cells SK-MEL-28 (ATCC, Catalog No.: HTB-72), NCI-H441 (ATCC, Catalog No.: HTB-174), NCI-H1975 (ATCC, Catalog No.: CRL-5908), NCI-H526 (ATCC, Catalog No.: CRL-5811), NCI-HCC827 (ATCC, Catalog No.: CRL-2868), Hs746T (ATCC, Catalog No.: Hs746T) and other cells were cultured according to the corresponding culture conditions. After cell digestion, the cells were counted and inoculated, and grown overnight in 96-well culture plates, with a density of 500 cells per well. At the same time, an equal volume of gradient dilutions of ADC were added. Cell viability was determined 6-7 days later using the CellTiter-Glo Luminescent Cell Viability Assay Kit (Promega) as described in the manufacturer's protocol. Cell viability was assessed as a percentage of control untreated cells.

[0552] like Figures 4A-4CAs shown, ADC drugs have different killing activities on tumor cell lines with different antigen expressions. The results show that the in vitro cell killing ability of R0108M3-9106DAR8, HuPR003M25-9106DAR8 and BMK1-MMAE DAR8 molecules is positively correlated with the target expression abundance.

[0553] Example 21. Comparison of in vivo antitumor activity of HuPR003M25-9106 DAR4, HuPR003M25-9106 DAR8 and PR0108M3-9106 DAR8 in a subcutaneous transplant tumor model of CD228 expressing cells in mice

[0554] The antitumor activity of A2058 and MDA-MB-231 was evaluated in mouse subcutaneous xenograft models.

[0555] A2058 subcutaneous xenograft tumor model: A2058 cells were cultured and 1.0 x 10 7 / 0.1mL (PBS) A2058 cells were inoculated on the right side of the back of Balb / c nude mice (purchased from Vital River). The average tumor volume reached 100-150mm 3 The mice were grouped according to tumor volume and body weight. The drugs were administered by intraperitoneal injection starting from the day of grouping (D0), once a week for a total of 3 times. The tumor volume and body weight were measured twice a week and the data were recorded.

[0556] MDA-MB-231 subcutaneous xenograft tumor model: MDA-MB-231 cells were cultured and 1×10 7 +Matrigel / 0.2ml MDA-MB-231 cells were inoculated subcutaneously on the right back of Balb / c nude mice (purchased from Beijing Weitong Lihua), and the average tumor volume reached ~100-150mm 3 The mice were grouped according to tumor volume and body weight. The drugs were administered by intraperitoneal injection starting from the day of grouping (D0), once a week for a total of 3 times. The tumor volume and body weight were measured twice a week and the data were recorded.

[0557] Tumor volume V = 1 / 2 × a × b 2 , where a and b represent length and width, respectively. Relative tumor volume RTV = Vt / V0, Vt is the tumor volume at the end of the experiment, and V0 is the tumor volume at the time of grouping. TGI represents the maximum tumor growth inhibition during the experiment. TGI = [1-RTV (experimental group) / RTV (control group)] × 100%. As mentioned above, PBS was used as a negative control.

[0558] The experimental data were expressed as mean ± standard error (SEM), and the graphs and statistical analysis were performed using GraphPad Prism 9 software. The significant differences in tumor volume were compared. One-way analysis of variance was used, and multiple comparisons were performed if F was significant. Tumor volumes were compared on the last day of the experiment.

[0559] The results of the A2058 subcutaneous xenograft tumor model are shown in Tables 37 and 38. Figure 5A , 5B The in vivo results showed that HuPR003M25-9106 DAR4, HuPR003M25-9106 DAR8, PR0108M3-9106 DAR8 and BMK1-MMAE DAR8 all had good anti-tumor activity, and the anti-tumor activity of HuPR003M25-9106 DAR8 was significantly better than that of HuPR003M25-9106 DAR4. There was no significant difference between HuPR003M25-9106 DAR8 and PR0108M3-9106 DAR8. Figure 5B As shown, the experimental animals were in good condition of activity and eating during the administration period, indicating that the test drug had no obvious toxic side effects on the experimental animals, and the animals had good tolerance and safety to the toxin.

[0560] Table 37. Tumor volume of A2058 xenograft subcutaneous tumor model under the action of HuPR003M25-9106-DAR 4 and DAR8 and PR0108M3-9106-DAR 8

[0561]

[0562] Table 38. Antitumor activity of HuPR003M25-9106-DAR 4 and DAR8 and PR0108M3-9106-DAR 8 in A2058 subcutaneous xenograft tumor model

[0563] ADC Dosage / Route / Regimen TGI (%) Vechile (PBS) ip / QW*3 - HuPR003M25-9106-DAR4 5mpk 5 mg / kg / ip / QW*3 70 HuPR003M25-9106-DAR4 10mpk 10 mg / kg / ip / QW*3 79 HuPR003M25-9106-DAR8 2.5mpk 2.5 mg / kg / ip / QW*3 90 HuPR003M25-9106-DAR8 5mpk 5 mg / kg / ip / QW*3 95 PR0108M3-9106-DAR8 2.5mpk 2.5 mg / kg / ip / QW*3 95 PR0108M3-9106-DAR8 5mpk 5 mg / kg / ip / QW*3 102 BMK1-MMAE-DAR8 3mpk 3mg / kg / ip / QW*3 101

[0564] The results of the MDA-MB-231 subcutaneous xenograft tumor model are shown in Tables 39 and 40. Fig. 6A , 6B In vivo results showed that HuPR003M25-9106 DAR4, HuPR003M25-9106 DAR8, PR0108M3-9106 DAR8 and BMK1-MMAE DAR8 all had good tumor suppressor activity. Figure 6B As shown, the experimental animals were in good condition of activity and eating during the administration period, indicating that the test drug had no obvious toxic side effects on the experimental animals, and the animals had good tolerance and safety to the toxin.

[0565] Table 39. Tumor volume of MDA-MB-231 subcutaneous xenograft tumor model under the action of HuPR003M25-9106-DAR 4 and DAR8 and PR0108M3-9106-DAR 8

[0566]

[0567] Table 40. Antitumor activity of HuPR003M25-9106-DAR 4 and DAR8 and PR0108M3-9106-DAR 8 in MDA-MB-231 subcutaneous xenograft tumor model

[0568] ADC Dosage / Route / Regimen TGI (%) Vechile (PBS) ip / QW*3 - HuPR003M25-9106-DAR4 1mpk 1mg / kg / ip / QW*3 98 HuPR003M25-9106-DAR4 3mpk 3mg / kg / ip / QW*3 108 HuPR003M25-9106-DAR8 0.5mpk 0.5 mg / kg / ip / QW*3 87 HuPR003M25-9106-DAR8 1.5mpk 1.5 mg / kg / ip / QW*3 127 PR0108M3-9106-DAR8 0.5mpk 0.5 mg / kg / ip / QW*3 109 PR0108M3-9106-DAR8 1.5mpk 1.5 mg / kg / ip / QW*3 129 BMK1-MMAE-DAR8 3mpk 3mg / kg / ip / QW*3 97

[0569] Example 22. HuPR003M25-9106 DAR8 and PR0108M3-9106 DAR8 Mouse Plasma Stability Assay

[0570] Six nude mice (common grade, animal source: Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.) were used and divided into two groups, and PR0108M3-9106-DAR8 and HuPR003M25-9106-DAR8 were injected into the tail vein respectively. The single dose was set at 5 mg / kg, and the administration volume was 10 mL / kg (diluted with 0.9% sodium chloride injection).

[0571] For the above experimental mice, blood was collected at the following time points: 0.5h, 4h, 24h, 72h, 7d, 14d, and 17d after the first administration. The blood drug concentration was detected by ELISA. The plate was coated with anti-hFc or anti-9106 and incubated overnight at 4°C. After washing once with 300μL PBST buffer, the diluted test serum was added and incubated at room temperature for 1 hour. Each tube of serum was tested on two plates. After a serum plate was washed three times with 300μL PBST buffer, 100μL HRP-labeled sheep anti-human IgG Fc solution was added to each well and incubated at room temperature for one hour. After washing five times with PBST buffer, the color development solution was added, the stop solution was added after the color development was completed, and the OD450 was read by the microplate reader. The non-compartmental model of Phoenix software was used to calculate the PK parameters.

[0572] Results Figure 7 Table 41 shows that PR0108M3-9106-DAR8 and HuPR003M25-9106-DAR8 have similar pharmacokinetic characteristics to monoclonal antibodies, and the linker has good plasma stability.

[0573] Table 41. Pharmacokinetic parameters of PR0108M3-9106-DAR8 and HuPR003M25-9106-DAR8 molecules in mice

[0574]

[0575] Although the specific embodiments of the present disclosure are described above, those skilled in the art should understand that these are only examples, and various changes or modifications can be made to these embodiments without departing from the principles and essence of the present disclosure. Therefore, the protection scope of the present disclosure is limited by the appended claims.

Claims

1. An anti-CD228 antibody or an antigen-binding fragment thereof, comprising heavy chain and light chain variable regions, wherein the heavy chain and light chain variable regions comprise: (1) HCDR1 as shown in SEQ ID NO: 36, HCDR2 as shown in X1ITYX2GSNTYNPSLKX3, HCDR3 as shown in SYYGRGX4, and LCDR1 as shown in KASX5X6INNRLA, LCDR2 as shown in GX7X8SX9ET and QQYX 10 LCDR3 represented by STPYT; wherein X1 is selected from Y or S; X2 is selected from D, E or S, X3 is selected from N or S, X4 is selected from M or S, X5 is selected from Q, E, S or N, X6 is selected from D, S or N, X7 is selected from A or S, X8 is selected from T or S, X9 is selected from L or R, X 10 Selected from W or D; or (2) HCDR1 as shown in SEQ ID NO: 54, HCDR2 as shown in TITX1X2GSYTYYPDNVKG, HCDR3 as shown in SEQ ID NO: 56, and LCDR1 as shown in X3ASQNVGTAVA, LCDR2 as shown in SEQ ID NO: 83 and LCDR3 as shown in SEQ ID NO: 84; wherein X1 is selected from D or E, X2 is selected from A or G, and X3 is selected from K, R, Q, W or S.

2. The anti-CD228 antibody or antigen-binding fragment thereof according to claim 1, comprising heavy chain and light chain variable regions, wherein the heavy chain and light chain variable regions comprise: (1) HCDR1 as shown in SEQ ID NO: 36, HCDR2 as shown in X1ITYX2GSNTYNPSLKX3, HCDR3 as shown in SYYGRGX4, and LCDR1 as shown in KASX5X6INNRLA, LCDR2 as shown in GX7X8SX9ET and QQYX 10 LCDR3 represented by STPYT; wherein X1 is selected from Y; X2 is selected from D, E, X3 is selected from N, X4 is selected from M or S, X5 is selected from Q, E, X6 is selected from D, X7 is selected from A, X8 is selected from T, X9 is selected from L, X 10 Selected from W; or (2) HCDR1 as shown in SEQ ID NO: 54, HCDR2 as shown in SEQ ID NO: 177, HCDR3 as shown in SEQ ID NO: 56, and LCDR1 as shown in X3ASQNVGTAVA, LCDR2 as shown in SEQ ID NO: 83 and LCDR3 as shown in SEQ ID NO: 84; wherein X3 is selected from K or W.

3. The anti-CD228 antibody or antigen-binding fragment thereof according to claim 2, comprising heavy chain and light chain variable regions, wherein the heavy chain and light chain variable regions comprise: (1) HCDR1 as set forth in SEQ ID NO:36, HCDR2 as set forth in SEQ ID NO:184, HCDR3 as set forth in SEQ ID NO:186, and LCDR1 as set forth in SEQ ID NO:190, LCDR2 as set forth in SEQ ID NO:67, and LCDR3 as set forth in SEQ ID NO:68; or (2) HCDR1 as set forth in SEQ ID NO:54, HCDR2 as set forth in SEQ ID NO:177, HCDR3 as set forth in SEQ ID NO:56, and LCDR1 as set forth in SEQ ID NO:82, LCDR2 as set forth in SEQ ID NO:83, and LCDR3 as set forth in SEQ ID NO:84; or (3) HCDR1 shown in SEQ ID NO:54, HCDR2 shown in SEQ ID NO:177, HCDR3 shown in SEQ ID NO:56, and LCDR1 shown in SEQ ID NO:182, LCDR2 shown in SEQ ID NO:83 and LCDR3 shown in SEQ ID NO:

84.

4. The anti-CD228 antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, wherein: (1) the heavy chain variable region sequence is as shown in SEQ ID NO: 157 or has at least 90%, 95%, 99% sequence identity thereto, and the light chain variable region sequence is as shown in SEQ ID NO: 168 or has at least 90%, 95%, 99% sequence identity thereto; or (2) the heavy chain variable region sequence is as shown in SEQ ID NO: 129 or has at least 90%, 95%, 99% sequence identity thereto, and the light chain variable region sequence is as shown in SEQ ID NO: 111 or has at least 90%, 95%, 99% sequence identity thereto; or (3) the heavy chain variable region sequence is as shown in SEQ ID NO: 129 or has at least 90%, 95%, 99% sequence identity thereto, and the light chain variable region sequence is as shown in SEQ ID NO: 144 or has at least 90%, 95%, 99% sequence identity thereto; Preferably, (1) the heavy chain variable region sequence is as shown in SEQ ID NO: 157, and the light chain variable region sequence is as shown in SEQ ID NO: 168; or (2) the heavy chain variable region sequence is as shown in SEQ ID NO: 129, and the light chain variable region sequence is as shown in SEQ ID NO: 111; or (3) The heavy chain variable region sequence is shown in SEQ ID NO: 129, and the light chain variable region sequence is shown in SEQ ID NO:

144.

5. An anti-CD228 antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, wherein the antigen-binding fragment is selected from the group consisting of Fab, Fab', F(ab')2, single-chain antibody (scFv), single-domain antibody (sdAb), dimerized V region (diabody), disulfide-stabilized V region (dsFv) and an antigen-binding fragment of a peptide comprising CDRs.

6. The anti-CD228 antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, comprising an antibody constant region; wherein the heavy chain constant region is derived from human IgG1, IgG2, IgG3 or IgG4 or a variant thereof; and / or the light chain constant region is derived from human antibody κ, λ chain or a variant thereof; Preferably, the amino acid sequence of the heavy chain constant region is derived from human IgG1 or a variant thereof; and / or the light chain constant region is derived from human antibody κ chain or a variant thereof. More preferably, the amino acid sequence of the heavy chain constant region is as shown in SEQ ID NO: 134, and / or the amino acid sequence of the light chain constant region is as shown in SEQ ID NO:

135.

7. The anti-CD228 antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, comprising: (1) the heavy chain sequence shown in SEQ ID NO: 200 and the light chain sequence shown in SEQ ID NO: 201; (2) the heavy chain sequence shown in SEQ ID NO: 197 and the light chain sequence shown in SEQ ID NO: 198; (3) The heavy chain sequence shown by SEQ ID NO: 197 and the light chain sequence shown by SEQ ID NO:

199.

8. An isolated nucleic acid encoding the anti-CD228 antibody or antigen-binding fragment thereof according to any one of claims 1 to 7.

9. A vector comprising the isolated nucleic acid of claim 8. A host cell comprising the vector according to claim 9.

11. A method for preparing an anti-CD228 antibody or an antigen-binding fragment thereof, comprising culturing the host cell of claim 10 under conditions suitable for expressing the anti-CD228 antibody or the antigen-binding fragment thereof.

12. An antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, comprising the anti-CD228 antibody or antigen-binding fragment thereof according to any one of claims 1 to 7 and a drug; wherein the drug is selected from the group consisting of: a cytotoxic agent, a radiolabel, a fluorophore, a chromophore, an imaging agent, an immunomodulator, an angiogenesis inhibitor, a cell proliferation inhibitor, a pro-apoptotic agent, a cell lytic enzyme, and any combination thereof; Preferably, the drug is selected from the group consisting of: DNA damaging agents, topoisomerase inhibitors, microtubule inhibitors, protein degraders, STING agonists, and any combination thereof.

13. The antibody-drug conjugate according to claim 12 or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, which has a structure represented by general formula (I): Pc-(LY-Dr)n P) in, Dr is the drug according to claim 12; Preferably, Dr is selected from the group consisting of camptothecin, auristatin, maytansinoid, vinca alkaloid, pyrrolobenzodiazepine (PBD), calicheamicin, duocarmycin, daunorubicin, doxorubicin, calicheamicin, anthramycin, neomycin, amatoxin, hemipteratin, eribulin, Tubulysin, and analogs or derivatives thereof; More preferably, Dr is selected from the group consisting of: Exatecan, MMAE, MMAF, MMAD, SN-38, DM1, DM4, pyrrolebenzodiazepine (PBD) dimer, and analogs or derivatives thereof; n is 1 to 10, preferably n is 2 to 8, more preferably n is 3 to 5 or 4 to 8, n is a decimal or an integer, and more preferably n is 2, 4, 6, 8; L and Y are joint units; Pc is the anti-CD228 antibody or antigen-binding fragment thereof according to any one of claims 1 to 7.

14. The antibody-drug conjugate according to claim 13 or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, which has a structure represented by the general formula (Pc-LY-Dr), general formula (II), general formula (III), or general formula (IV): in: Y is selected from -O-(CR a R b ) m -CR 1 R 2 -C(O)-, -O-CR 1 R 2 -(CR a R b ) m -, -O-CR 1 R 2 -, -NH-(CR a R b ) m -CR 1 R 2 -C(O)- or -S-(CR a R b ) m -CR 1 R 2 -C(O)-; R a and R b are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen, an alkyl group, a haloalkyl group, a deuterated alkyl group, an alkoxy group, a hydroxyl group, an amino group, a cyano group, a nitro group, a hydroxyalkyl group, a cycloalkyl group or a heterocyclic group; Or, R a and R b Together with the carbon atom to which it is attached, it forms a cycloalkyl or heterocyclyl group; R 1 is selected from halogen, haloalkyl, deuterated alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, heterocyclyl, aryl or heteroaryl; R 2 is selected from a hydrogen atom, a halogen, a haloalkyl group, a deuterated alkyl group, a cycloalkyl group, a cycloalkylalkyl group, an alkoxyalkyl group, a heterocyclyl group, an aryl group or a heteroaryl group; Or, R 1 and R 2 Together with the carbon atom to which it is attached, it forms a cycloalkyl or heterocyclyl group; Or, R a and R 2 Together with the carbon atom to which it is attached, it forms a cycloalkyl or heterocyclyl group; m is an integer from 0 to 4; n is 1 to 10, n is a decimal or an integer, preferably n is 2 to 8, more preferably n is 3 to 5 or 4 to 8, n is a decimal or an integer, further preferably, n is 2, 4, 6, 8; L is the joint unit; Pc is the anti-CD228 antibody or antigen-binding fragment thereof according to any one of claims 1 to 7.

15. The antibody-drug conjugate according to claim 14, or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, in: Y is -O-(CR a R b ) m -CR 1 R 2 -C(O)-; R a and R b are the same or different and are each independently selected from a hydrogen atom, a deuterium atom, a halogen or an alkyl group; R 1 is a halogenated alkyl or C 3-6 Cycloalkyl; R 2 is selected from a hydrogen atom, a haloalkyl group or a C 3-6 Cycloalkyl; Or, R 1 and R 2 Together with the carbon atom to which it is attached, it forms C 3-6 Cycloalkyl; m is 0 or 1.

16. The antibody-drug conjugate according to claim 14 or 15, or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, wherein Y is selected from:

17. The antibody-drug conjugate according to any one of claims 14 to 16, or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, wherein the O end of Y is connected to the linker unit L.

18. The antibody-drug conjugate according to any one of claims 14 to 17, or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, wherein the linker unit -L- is -L 1 -L 2 -L 3 -L 4 -, L 1 for s 1 is an integer from 2 to 8; L 2 is a chemical bond; L 3 is a tetrapeptide residue; L 4 For-NR 5 (CR 6 R 7 )t-,R 5 , R 6 or R 7 are the same or different and are each independently a hydrogen atom or an alkyl group, and t is 1 or 2.

19. The antibody-drug conjugate according to any one of claims 14 to 17, or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, wherein the linker unit -L- is -L 1 -L 2 -L 3 -L 4 -, L 1 for s 1 and 2 independently selected from integers from 0 to 8; preferably 1 is 2, s 2 is an integer from 2 to 8; more preferably, s 1 is 2, s 2 is 2, 3, 4, 5 or 6; L 2 is a chemical bond; L 3 is a tetrapeptide residue; L 4 For-NR 5 (CR 6 R 7 )t-,R 5 , R 6 or R 7 are the same or different and are each independently a hydrogen atom or an alkyl group, and t is 1 or 2.

20. The antibody-drug conjugate according to any one of claims 14 to 19, or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, wherein the linker unit -L-, wherein L 1 The end is connected to Pc, L 4 Connect the Y end.

21. The antibody-drug conjugate according to any one of claims 14 to 20, or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, wherein said L 3 The tetrapeptide residue is an amino acid residue formed by two or more amino acids selected from phenylalanine, glycine, valine, lysine, citrulline, serine, glutamic acid, and aspartic acid; preferably, the tetrapeptide residue is GGFG.

22. The antibody-drug conjugate according to any one of claims 14 to 21, or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, wherein the antibody-drug conjugate is selected from: wherein Pc and n are as defined in claim 14.

23. The antibody-drug conjugate according to any one of claims 14 to 22, or a pharmaceutically acceptable salt or solvate thereof, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or a mixture thereof, wherein the antibody-drug conjugate is selected from: wherein n is as defined in claim 14.

24. A kit comprising the anti-CD228 antibody or antigen-binding fragment thereof according to any one of claims 1 to 7, or the antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof according to any one of claims 12 to 23, or a tautomer, mesoform, racemate, enantiomer, diastereomer, or a mixture thereof.

25. A pharmaceutical composition comprising the anti-CD228 antibody or antigen-binding fragment thereof according to any one of claims 1 to 7, or the antibody-drug conjugate or a pharmaceutically acceptable salt or solvate thereof according to any one of claims 12 to 23, or a tautomer, mesoform, racemate, enantiomer, diastereomer, or a mixture thereof, and one or more pharmaceutically acceptable carriers.

26. Use of the anti-CD228 antibody or antigen-binding fragment thereof according to any one of claims 1 to 7, or the antibody-drug conjugate or pharmaceutically acceptable salt or solvate thereof according to any one of claims 12 to 23, or its tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or the pharmaceutical composition according to claim 25 in the preparation of a medicament for treating a disease or condition mediated by CD228; Preferably, the CD228-mediated disease or disorder is a CD228-expressing cancer.

27. Use of the anti-CD228 antibody or antigen-binding fragment thereof according to any one of claims 1 to 7, or the antibody-drug conjugate or pharmaceutically acceptable salt or solvate thereof according to any one of claims 12 to 23, or the pharmaceutical composition according to claim 25 in the preparation of a medicament for treating or preventing tumors or cancers; Preferably, the tumor or cancer is selected from the group consisting of melanoma, pancreatic cancer, mesothelioma, colorectal cancer, lung cancer, thyroid cancer, breast cancer, bile duct cancer, esophageal cancer and head and neck cancer.